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ABSTRACT OF THE DISSERTATION
MAGNETIC NANOPARTICLE-BASED TARGETED DRUG DELIVERY FOR
TREATMENT OF NEURO-AIDS AND DRUG ADDICTION
by
Vidya Sagar
Florida International University, 2013
Miami, Florida
Professor Madhavan Nair, Major Professor
Brain is one of the safe sanctuaries for HIV and, in turn, continuously
supplies active viruses to the periphery. Additionally, HIV infection in brain results
in several mild-to-severe neuro-immunological complications termed neuroAIDS.
One-tenth of HIV-infected population is addicted to recreational drugs such as
opiates, alcohol, nicotine, marijuana, etc. which share common target-areas in
the brain with HIV. Interestingly, intensity of neuropathogenesis is remarkably
enhanced due to exposure of recreational drugs during HIV infection. Current
treatments to alleviate either the individual or synergistic effects of abusive drugs
and HIV on neuronal modulations are less effective at CNS level, basically due to
impermeability of therapeutic molecules across blood-brain barrier (BBB).
Despite exciting advancement

of nanotechnology in drug delivery,

existing nanovehicles such as dendrimers, polymers, micelles, etc. suffer from
the lack of adequate BBB penetrability before the drugs are engulfed by the
reticuloendothelial system cells as well as the uncertainty that if and when the
nanocarrier reaches the brain. Therefore, in order to develop a fast, target-
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specific, safe, and effective approach for brain delivery of anti-addiction, anti-viral
and neuroprotective drugs, we exploited the potential of magnetic nanoparticles
(MNPs) which, in recent years, has attracted significant importance in biomedical
applications. We hypothesize that under the influence of external (non-invasive)
magnetic force, MNPs can deliver these drugs across BBB in most effective
manner. Accordingly, in this dissertation, I delineated the pharmacokinetics and
dynamics of MNPs bound anti-opioid, anti-HIV and neuroprotective drugs for
delivery in brain. I have developed a liposome-based novel magnetized
nanovehicle which, under the influence of external magnetic forces, can
transmigrate and effectively deliver drugs across BBB without compromising its
integrity. It is expected that the developed nanoformulations may be of high
therapeutic significance for neuroAIDS and for drug addiction as well.
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1. Introduction
1.1. AIDS epidemiology:
Acquired immune deficiency syndrome (AIDS) is one of the most sought
infectious diseases of the modern world (Castro-Nallar et al., 2012). It ranks
among the top four cause of death throughout the globe - particularly in Africa
and women of reproductive age group it is the number one cause of death
(MMWR, 2001; UNAIDS, 2012a). Since it was discovered in the early 1980s that
HIV is the causative agent of AIDS, about 65 million people throughout the world
have been estimated to be infected (ILO, 2012). The Sub-Saharan African region
remains the epicenter of this infection; however, certain other parts of the globe
such as the Caribbean Island, America, Eastern Europe and Central Asia also
fall in high alarm zones where HIV prevalence in adults are equal to or more than
0.5% (UNAIDS, 2010). Almost 34.2 million people are currently living with this
global pandemic where women account for half of the population (UNESCO,
2012; UNAIDS, 2012a). People from all age group including children and young
adolescent are affected by this pandemic. While Children (age 0-15) alone
constituted 10% of total people living with HIV in the year 2010 (UNAIDS, 2010),
42% of all new adult (15+ age) infections were found in the young aged 15-24
(UNAIDS, 2012b).
Human immunodeficiency virus (HIV) is transmitted mainly through sexual
contact, contaminated injection equipment, and/or mother-to-child transmission.
Sexual contact remains the primary source of transmissions and accounts for
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almost 80% of the HIV infections throughout the globe (Skar et al., 2011).
Mother-to-child transmission resulted in the birth of approximately 370, 000 HIV
positive children in 2009; nevertheless, this is a declining trend as compare with
2001 when nearly 500, 000 cases were estimated (UNAIDS, 2010). The
transmission of HIV as a result of contaminated injection continue to be the
matter of concern. Predominantly among intravenous drug abusers, sharing of
injection equipment is a common practice and thus, they are extremely
vulnerable to explosive outbreaks of HIV infections as have been seen in many
regions like Finland, Sweden, Thailand, and former Soviet Union. Globally,
almost 10% of HIV infections are related to injection drug use which accounts for
approximately one fifth of all injection drug users (UNAIDS/PCB, 2009; Skar et
al., 2011). This proportion is more alarming in the United States, and Eastern
Europe and Central Asia where, respectively, one third and one fourth of injection
drug users are HIV-infected (UNAIDS, 2010; UNODC, 2012). Similarly, higher
proportions of HIV infected people among injection drug users have been
estimated in places like Nairobi (36%), Zanzibar (27%), Myanmar (38%),
Thailand ( 30%-50%), Vietnam

(32% -58%), Indonesia (50%), Russian

Federation (37%) and, Ukraine (39%-50%-Kryvyi Rih-88%)( UNAIDS, 2010).
Implementation of antiretroviral therapies (ART) has come up as respite
for AIDS patients. Nearly 21% decline in the AIDS-related death rate has been
reported between the years 1997-2010 (The World Bank, 2012; UNAIDS, 2012).
Nonetheless, HIV/AIDS still remains unstoppable and incurable. Alarmingly,
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almost 7000 new individuals were infected every day throughout the globe in
2010 (Douce et al., 2012) and nearly 9 million people living with HIV lack access
of any of treatment (WHO, 2012). Additionally, quite unrealistically, uninterrupted
treatment for several years has been theorized for complete viral eradication with
existing ART (Perelson et al., 1997; Chun et al., 2007). Also, their therapeutic
values have been shown to of small benefit for associated complications such as
illness of central nervous system (CNS) (Vivithanaporn et al., 2011). Most
importantly, limited or zero reachability of most antiretroviral drugs to viral tissue
sanctuaries such as brain hampers the viral clearance and it is believed as the
main reason of resurgence of HIV from below detection level to outbreak on
interruption of the treatment (Varatharajan and Thomas., 2009; Douce et al.,
2012). These, in association with epidemiological data, indicate a less promising
trend towards faster eradication of HIV infections.

Thus, significant

improvements over the current therapies of HIV/AIDS are needed immediately.
1.2.

HIV, drugs of abuse and CNS impairment:
Nervous system alterations as a result of direct or indirect effect of HIV

infection, collectively known as neuroAIDS, are always associated with AIDS
patients. At least 10% of diagnosed cases are accompanied by some kind of
neurological illness (Almeida and Ellis, 2006) and further during the disease
progression approximately 50% cases demonstrate neuropathological signs or
symptoms (McArthur et al., 2005). In the same line, mild to severe neurological
alterations are seen in at least 80% autopsies of AIDS patients (Almeida and
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Ellis, 2006). Many CNS diseases such as viral and chronic meningitis, HIVassociated neurocognitive disorders (HAND), vacuolar myelopathy, peripheral
neuropathies, etc. have been coupled to the neurovirulent effects of HIV
(Letendre et al., 2009; Singer et al., 2010).
Previously it was believed that penetration of HIV into CNS occurs only
during the final stage of infection when higher load of virus is found in the
peripheral blood. Now it is putatively believed that virus may enter the CNS from
the onset of infection (Kramer-Hammerle et al., 2005). Towards this end,
presence of HIV-particles, -proteins, and -DNA in the CNS along with the
intrathecal production of anti-HIV antibodies have been seen during the initial
infection (Ho et al., 1985; Resnick et al., 1985; An SF and Scaravilli, 1997, Rolfs
and Schumacher, 1990; Davis et al., 1992; 1996; Gray et al., 1996; Almeida and
Ellis, 2006). HIV may enter into CNS either directly or as “Trojan passenger” via
trafficking of infected monocytes, macrophages, and/or T-cells across the tightly
junctioned brain microvascular endothelial cells (BMECs) of blood-brain barrier
(BBB) (Albright et al., 2003; Ghafouri et al., 2006). Initial infection of HIV in the
CNS triggers production of proteins that alter the BBB integrity (e.g. matrix
metalloproteinase) (Sporer et al., 1998; Conant et al., 1999) and influence
leukocytes transmigration across this barrier (e.g., monocyte chemotactic
protein-1) (Boven et al., 2000). These intensify the HIV infection resulting in
degradation of BBB and CNS injury. Numbers of viral proteins have been shown
to induce the HIV neurotoxicity and associated pathology. Particularly, HIV
protein gp120 and Tat have been extensively studied. Both, gp120 and Tat can
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breach BBB independent of viral penetration and can be toxic across multiple
species and cell lines. Several neuropathological features are noticed due to
treatment of these proteins (Ghafouri et al., 2006; Ferris et al., 2008).
As discussed earlier, spread of HIV infection and drug abuse are
significantly interlinked. Along the same line, drug abuse can alter the
neuroplasticity and damage the CNS analogous to that happens during the HIV
infections (e.g., loss of dopaminergic neurons) (Nath et al., 2002; Burdo et al.,
2006). Most importantly, many illicit drugs have been shown to promote
susceptibility/progression of HIV infections and associated neuropathogenesis.
This stimulation of neuropathogenesis in drug-addicted AIDS patients can be
attributed to the concerted effect of HIV (or its protein) and drugs of abuse on
neurotoxicity. All sorts of abusive drugs such as psychomotor simulants
(Amphetamines), opiates (cocaine, morphine), alcohol, nicotine, marijuana, etc.
have

been

shown

to

cause

concerted

effect

on

the

HIV-associated

neuropathogenesis in one or other way (Hauser et al., 2007; Ferris et al., 2008;
Rogers, 2011). For examples, the immunomodulatory actions of opioids induce
the expression of µ and other chemokine receptors in monocytic cells resulting in
increased HIV susceptibility and stimulation of HIV expression (Peterson et al.,
1993; 1999; Rogers et al., 2000). Also, opiates enhance the production of
proinflammatory factors like MCP-1, RANTES, IL-6, ROS, etc. in the brain cells
such as neurons, astroglia and microglia (Peterson et al., 1998; El-Hage et al.,
2005). These exacerbate the preexisting inflammation of neurons as a
consequence of HIV infections. Additionally, alteration in endogenous opioids
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level cause disruption of dopaminergic functions which affect the neuroimmunological ability of nervous system to respond against HIV (Hauser et al.,
2005; Reddy et al., 2012). Psychostimulants such as methamphetamine and
cocaine have also been shown to disrupt the dopamine level resulting in
oxidative damage of neurons (Cubells et al., 1994; Brown and Yamamoto, 2003;
Riddle et al., 2006). Likewise, alcohol exposure alters the BBB permeability
which leads to increased HIV entry and ROS level in the brain via influx of
macrophages (Haorah et al., 2004; 2005; Persidsky et al., 2006). Thus, a
concerted effect of drugs of abuse and HIV infection result in sever
neurobiological alterations.

Figure1. Simplified overview of the common pathways involved in HIV and Recreational drugs
induced neuropathogenesis.
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1.2.1. Neurobiology of morphine addiction and effect on HIV infection:
Morphine, a μ opioid receptor agonist is a highly potent analgesic drug. It
is highly addictive resulting in rapid development of tolerance, physical and
psychological dependence (Coller and Hutchinson, 2012). Several attempts have
been made in the past to understand the neurobiology of opiate addition (Nath et
al., 2002; Burdo et al., 2006; Hauser et al., 2007; Ferris et al., 2008; Rogers,
2011). There are various hypotheses that describe morphine addition that
includes the alteration in affinity or number of opioid receptors (Simonato, 1995),
changes in specific brain regions, alterations in neurotrophin signaling pathways
that regulate the non-adrenergic response of Locus Coeruleus (LC) neurons to
opiates (Hatami et al., 2007) and role of glutamate receptors (Inoue et al., 2003).
Thus, morphine tolerance and addiction involve intricate mechanism involving
dopaminergic, noradrenergic and glutamatergic neurons. Due to this complexity,
opioid dependence is proposed to involve multicellular event, where individual
neurons differentially adapt based on the signals they receive and the second
messengers and genetic programming of the cell (Simonato, 1995). The exact
mechanism by which opiate acts as a cofactor for HIV infection is not clear.
However, it is reported that μ opioid ligands act synergistically with HIV proteins
(tat; transactivator and gp120) to potentiate the HIV-related neurotoxicity.
Further, morphine upregulates the expression of HIV entry coreceptors CCR3
and CCR5 on astrocytoma cells, which increases viral binding and entry into the
cells and promotes viral replication (Stefano et al., 1996). In recent years, the
role of astrocytes and microglia in the neuropathogenesis of HIV is becoming
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increasingly evident. Therefore, use of a μ opioid receptor antagonist in addition
to ART could be of therapeutic importance and may provide significant benefits in
treatment of HIV infected subjects who are opiate users. CTOP (D-Pen-Cys-TyrDTrp-Orn-Thr-Pen-Thr-NH2) is a highly selective and potent μ receptor
antagonist; however it is impenetrable through the Blood Brain Barrier (BBB).
The current study proposes to bind CTOP to the magnetic nanoparticles and
target to the brain using an in vitro BBB model.

1.3.

Problems of neuroAIDS treatments:

1.3.1. Limitations of current treatments:
Highly active anti-retroviral therapy (HAART) has been successfully
implemented for management and prevention of AIDS progression. Antiretroviral
(ARV) drugs recommended by WHO for HAART formulations belongs to seven
classes: Nucleotide Reverse Transcriptase Inhibitors (NtRTI), Nucleoside
Reverse Transcriptase Inhibitors (NRTI), Non- Nucleoside Reverse Transcriptase
Inhibitors (NNRTI), Protease Inhibitors (PI), Fusion Inhibitors (FI), Integrase
Inhibitors (InI), and CCR5 antagonists (AIDSinfo-NIH, 2012). Basically,
combinations of three or more class of antiretroviral (ARV) drugs are formulated
for HAART regimens. With the proper HAART treatment plasma viral load can
decline below the detection limit (Douce et al., 2012) and median life expectancy
of AIDS patients may also rise by tenfold (Vyas et al., 2006; Mallipeddi and
Rohan, 2010). In fact, HAART has resulted in remarkable decline in the mortality
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rate of AIDS Patients during the last decade and it is predicted that 50% of HIVinfected people will cross the age of 50 by 2015 (Smith, 2005, Holt et al., 2012).
Undoubtedly, as a result of HAART, this lethal disease has been transformed into
a chronic pathology. Nevertheless, little irregularity or interruption of HAART
treatment lead to resurgence of suppressed viral replication (Douce et al., 2012)
and so, challenge of complete restriction or elimination of progression of HIV
infections still exist.
A dramatic decrease in morbidity of many AIDS related symptoms is
noticed following the HAART treatment. In the same line, occurrence of some of
the neuronal disabilities has also been remarkably declined (e.g. HIV associated
dementia (HAD) and symptomatic distal sensory polyneuropathy has been
reduced to less than 7 and 10 % of affected people respectively) (Antinori et al.
2007; Woods et al. 2009; Vivithanaporn et al., 2010). Nevertheless, a
concomitant rise in the other form of CNS dysfunction such as minor cognitive
impairments/motor disorders has widely been noticed in the patients on HAART
regimes (Fischer-Smith and Rappaport, 2005; Ghafouri et al., 2006; Kraft-Terry
et al., 2010; Wong et al., 2010). This resulted in an increase in the cumulative
occurrence of HIV associated neurocognitive complications. Vivithanaporn et al.,
(2010) reported that during the decades of 1998-2008, at least 25% of HAART
treated patients developed one or other neurological syndrome. Thus, burden of
HIV associated neurological disorders prevail on larger scale. This reduced
efficacy of current HAART regimens for treatment of increased incidence of
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neuroAIDS can be attributed to many reasons. Firstly, these treatments are not
targeted for inflammatory cascades underlying any of the HIV-associated
neuronal disorders. Thus, HAART does not have direct effect on the HIV
associated inflammatory degeneration (Rumbaugh et al., 2009). Secondly,
inadequate reachability of ARV drugs across the brain barriers has minimum
effect on the resting viral loads in the brain hideout. This may result in gradual
generation of resistance viral strain against HAART as has been seen in some of
the infected populations (Vella and Palmisano, 2005; Amiji et al., 2006; Kozal,
2009; Griffiths, 2009; Nijhuis et al., 2009; Gupta and Jain, 2010). Third, and
importantly, inadequate CNS reachability of ARV drugs, which is also the main
obstacle towards treatment of neuroAIDS, is caused due to impermeability of
drugs across the brain barriers. This can be attributed to properties of brain
barriers that make it ultra-selective permeable for both, endogenous compounds
and xenobiotic molecules as well. Additionally, ARV drug’s short half-life and low
bioavailability, due to extensive first pass metabolism including gastrointestinal
degradation, may also add to their insignificant arrival in the CNS (Gupta and
Jain, 2010; Wong et al., 2010). Moreover, emergence of various side effects and
cost of HAART may also result in cessation of treatment (Nolan et al., 2005;
Douce et al., 2012). Overall, the basic problem of HAART failure in treatment of
neuroAIDS lies in the structural and functional complexity of brain barriers.
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1.3.2. Barriers of CNS:
The organizational uniqueness of CNS is featured by three structural
barriers, namely, the BBB, blood-cerebrospinal fluid barrier (BCSFB), and the
Cerebrospinal fluid-brain barrier (CSFB). In particular, the BBB and BCSFB are
very special anatomical features because they safeguard the brain from the
periphery, respectively by means of tightly junctioned brain microvessel
endothelial cells (BMECs) and choroid epithelial cells. These tightly packed
structures possess very low and selective paracellular permeability. In contrast,
CSFB may not be considered as an anatomical barrier because it is structured by
loosely linked ventricular ependymal cells and can readily allow reversible
diffusion of solutes from ventricular cerebrospinal fluid (CSF) to brain
parenchyma or vice versa (Enting et al., 1998; McGee et al., 2006; Johanson et
al., 2011).
The BBB function as the interface that separates the brain parenchyma
(CNS) from the blood stream (peripheral circulation). It is an extensive,
continuous, fenestrationless, and almost impermeable barrier of tightly junctioned
BMECs along the capillaries lining throughout the cerebral microvasculature. The
tightness of this transendothelial junction is 50-100 folds higher than the
peripheral vessels, giving an electrical resistance of 1500-2000 Ωcm-2(Crone and
Christensen, 1981; Butt et al., 1990; Gonzalez-Mariscal et al., 2003; Weksler et
al., 2005; Hamilton et al., 2007; Wang and Bordey, 2008). This indicates the
severity of opposition-intensity to the passage of molecules from entering the
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cerebral space. The structural sophistication of the BBB is further compounded
by persistent and intimate contact of BMECs to other neuronal cells, mainly
pericytes and perivascular astrocytes (Hawkins and Davis, 2005; Abbott et al.,
2006). The integrity of tight junctions is maintained by three main tight junction
transmembrane integral proteins, occludin, claudin and junction adhesion
molecules and many cytoplasmic accessory proteins, such as zonula occludens,
cingulin, 7H6 antigen, etc. (Citi et al., 1988 ; Hirase et al., 1997; Haskins et al.,
1998; Denker and Nigam, 1998; Furuse et al., 1999). Additionally, BMECs
possess few pinocytotic vesicles and its mitochondrial content (both quantity and
volume) is also high which, respectively, limit the transcytosis and fuel the
increased demand of transport activity associated with the endothelial influxefflux pump (Enting et al., 1998). Only selected molecules necessary for ideal
functional efficiency of the brain such as certain amino acids, monocarboxylic
acids, amines, sugars, purine bases, hydrophilic molecules like O2 and CO2, etc.
is actively transported via mechanisms such as carrier mediated transport, fluidphase endocytosis, receptors- or absorptive -mediated endocytosis (King and
Johnson, 1985; Gonatas et al., 1984; Fishman et al., 1987; Dehouck et al., 1994;
Descamps et al., 1996; Tsuji and Tamai, 1999; Tamai and Tsuji, 2000; Wolka et
al., 2003; Yousif et al., 2007; Hamilton et al., 2007; Zhang, 2010). Many
substrate specific transporters such as monocarboxylate transport system,
glucose transporter-1, insulin receptor, transferrin receptor, ceruloplasmin
receptor, etc are present on the BMECs (Wong et al., 2012). Also, certain
neurotransmitters and small lipophilic xenobiotics or endogenous molecules up to
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molecular weight of 600 Dalton can freely diffuse transcellularly across the BBB
(Pardridge, 2001). However, all these mode of selective permeability and
transportation of small lipophilic or other drug molecules across the BBB provide
very little or no benefit for the management of most brain diseases.
Transportation of small or large drugs in the CNS, in overall, is also critically
affected due to functional sophistication of the BBB. Regardless of the drug’s
ability or inability to permeate the BBB, their active percentage in the CNS
remains below the pharmacological significant level in most cases including
many ARV drugs. Towards this end, endothelium of the BBB is equipped with
large spectrum of influx-efflux receptors/proteins that can actively transport
molecules such as nutrients, metabolites, hormones, neurotransmitters, peptides,
drugs, etc in or out of the brain. These transporters have been classified into two
main groups, namely, ATP-binding cassette (ABC) transporters and solutecarrier (SLC) superfamily. Major ABC transporters and SLC carriers that affect
drug delivery across the BBB are P-glycoprotein (P-gp), breast cancer resistance
protein (BCRP), multi-drug resistance-associated proteins (MRPs), organic
cation transporter (OCTs), organic anion transporters (OATs), organic anionstransporting polypeptide (OATPs), equilibriative and concentrative nucleoside
transporters (ENTs and CNTs), system L-transporters, etc. Many of these
carriers have been shown to affect the distribution of ARV drugs across the BBB
(Ronaldson et al., 2008; Varatharajan and Thomas, 2009). An anti-HIV drug may
serve as substrate, inhibitor or both for different influx-efflux transporters or, in
other words, these transporters possess overlapping specificity for ARV drugs.
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Such as, Abacavir, an NRTI, is a substrate for ABC transporters, P-gp and
BCRP; and simultaneously, it functions as an inhibitor of other ABC transporters,
MRP-1, 2 and 3 (Pan et al., 2007; Shaik et al., 2007; Weiss et al., 2007; Giri et
al., 2008). Similarly, Nelfinavir, a PI, is substrate for P-gp and inhibitor of BCRP
and two SLC superfamily transporters, OCT-1 and 2 (Kim et al., 1998; Gupta et
al., 2004; Jung et al., 2008). While being a substrate of efflux transporters causes
own inaccessibility to the target, as inhibitor of influx transporters it blocks the
CNS entry of corresponding useful substrates. Further, as inhibitors of efflux
transporters, an ARV drug may influence the targeted delivery-kinetics of
corresponding drug substrate and this may be reason for positive or negative
drug interaction during successful or failed recipe of a combined ART therapy.
BEMCs also possess enzymatic barrier for metabolization of undesirable
neuroactive substances recruited through blood (Minn et al., 1991; Brownson et
al., 1994). Elevated expressions of various enzymes such as γ-glutamyl
transpeptidase, aromatic acid decarboxylase, alkaline phosphatase, etc are
found in cerebral microvessels. Metabolism-dependent luminal or abluminal
expression of these enzymes significantly affects the dynamics and kinetics of
xenobiotics in the brain (Betz et al., 1980; Hau, 2005). Thus, in order to maintain
the brain homeostasis, various structural and functional uniqueness of the BBB
allow exogenous molecules at zero level or far below the pharmacological
significant amount. Therefore, the BBB may be considered as the primary
impediment that prevents drug penetration into the CNS.
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The BCSFB, at the choroid plexus in ventricles, also restricts flux of ions
and molecules from the blood into the brain. Anatomically, tightly junctioned
monolayer of choroid epithelial cells surrounds highly permeable fenestrated
endothelium of choroid capillaries. This creates a barrier between the
extracellular blood filtrate from these capillaries and the CSF in the brain
ventricular spaces. The epithelium of this barrier possesses a special
combination of basal labyrinth contacting the blood filtrates and profuse apical
microvilli towards the CSF. This unique structural arrangement affords necessary
surface area for appropriate transport physiology of solute and water exchange
across the BCSFB (Enting et al., 1998; McGee et al., 2006; Johanson et al.,
2011). The functional sophistication of the BCSFB is similar to that of the BBB in
many ways. As such, dense mitochondrial content and various influx/efflux
receptors and transporters belonging to ABC and SLC superfamily are also
present in choroid epithelial cells (Varatharajan and Thomas, 2009; Wong et al.,
2012). However, BCSFB is quantitatively more permeable and possesses unique
transportability for many compounds and molecules such as Ca2+, iodide,
homovanillic acid etc (Siegel et al., 1999). Various transportation processes such
as low capacity transcellular pinocytosis/exocytosis, limited facilitated or nonfacilitated paracellular diffusion, and receptors-transporters mediated active
passage have been demonstrated in the BCSFB. Additionally, presence of few
incomplete junctions at this barrier is putatively believed to allow protein/peptides
movement within a limit. Importantly, brisk blood flow at the choroid plexus (~10
times more than the brain) increases the overall concentration of metabolites in
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the extracellular blood filtrate from capillaries leading to increased passage
probability across the BCFB via relevant transportation routes (Johanson et al.,
2011). Nevertheless, most xenobiotics remain impermeable to the BCSFB. Even
most of the transportable metabolites could be secreted in the ventricular CSF by
epithelial cells and must diffuse into brain parenchyma to be effective. Notably,
the CSF from both, choroidal (epithelium) and extrachoroidal (from brain
capillaries and ventricular wall) secretion is deposited in the ventricular spaces.
Basically, the CSF serves as “sink” that collects metabolic waste and other
molecules from the brain in a gradient dependent manner and releases them
over the brain. This helps to maintain the steady-state concentrations of various
endogenous molecules and xenobiotics that penetrate into the brain or CSF
(Davson et al., 1961). The CSF from ventricles passes into cerebral- and spinalsubarachnoid spaces where it is separated from the direct blood contact via the
tight arachnoid membrane. Arachnoid membrane contains arachnoid villi for
absorption and unidirectional exit of the CSF and its metabolites into the venous
sinuses over the brain surface. The CSF in the ventricular and subarachnoid
spaces may also reversibly diffuse into brain interstitium through loosely linked
ependyma of CSFB and pia-glial membranes respectively. Diffused compound
from CSF to brain interstitium can reach to parenchyma (neurons and glial cells)
or/and may face the BBB along the cerebral microvasculature (Johanson et al.,
2011). However, diffusion of such metabolites to the parenchyma is remarkably
hampered due to rapid rate of the CSF turnover (~ 4 times per day) (Davson and
Segal, 1996; Siegel et al., 1999). The CSF convection and bulk flow towards the
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exit rout through arachnoid villi is much faster than drugs diffusion from the CSF
to the brain parenchyma leading to rapid removal of CSF metabolites. Also,
larger distance between the CSF and brain interstitial fluid decreases the
diffusion process (Pardridge, 2011). Thus, presence of drugs in the CSF does
not guarantee its passage to the brain. Large molecular weight molecule and
hydrophilic compounds are more frequently released due to sink effect. As such,
azidothymidine (AZT), an ARV drugs, can enter the CSF probably either as a
result of their bulk flow movement or using the choroid thymidine transporter;
however, it never reaches to the brain (Wu et al., 1992). Overall, we see that with
the novel molecular, structural, and functional arrangements, BCFB can be
considered as the secondary barrier that prevents drug penetration into the CNS.
1.4.

Advantages of nano-scale technology in drug-delivery:
Nanotechnology harvests the unique physicochemical parameters of

materials at a nanometer size range. Few of the intrinsic properties of
nanoparticles such as higher specific surface area and increased circulation
time have shown remarkable potential for their use as novel drug carrier. Also,
other properties like biocompatibility, surface charge, hydrophobicity, and
crystallinity are among the fundamental considerations for selection of a
nanoparticle in the field of medicine (Semete et al., 2010). The concept of nanodrugs revolves around development of “target-specific, effective, safe and
controllable” drug-delivery method which is need of the hour. Basically, drugs,
alone or in association/combination with target-specific molecules, are enclosed
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in or absorbed on nanoparticles for better efficacy and lesser side effects (Liu et
al., 2010).
Superiority of the nano-drug delivery methods could be attributed to
combinations of its various features. Firstly, a dramatic increase in the
bioavailability of drugs can be achieved through nano-drugs or nano drugdelivery carrier. As such, a significant amount of orally administered nanocapsulated drugs (<100 nm) escape the portal blood circulation route avoiding
the reticuloendothelial digestion; rather they are passed to systemic circulation
via intestinal lymphatic transport resulting in remarkable reduction in the first
pass hepatic metabolism which enhance their quantity and duration of
bioavailability. Further, because of the ability to freely flow into capillaries and
remarkable increase in blood circulation time, nanoparticles can travel to
tissues in every nook and corner of the body (McNeil, 2005; Desai et al., 1996;
1997). The nano-size particles are compatible for easy intracellular uptake and
can even travel across different physiological barriers such as BBB, stomach
epithelial, etc (Koziara et al., 2003). The increased circulation time and higher
cellular uptake of nanoparticles is greatly influenced by their surface charge and
hydrophobicity/hydrophilicity (besides size). While coating of nanoparticles with
positively charged molecules such as chitin enhances their attachment to
negatively charged surface of cells, coating with hydrophilic compounds (e.g.
polyethylene glycol, pluronics, etc) circumvent opsonization resulting in longer
blood circulation time (Freiberg and Zhu, 2004; Mohanraj et al., 2006; Park et
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al., 2010). The hydrophobic/hydrophilic nature of nanocarriers also affects the
solubility of weaker hydrophilic drugs, and thus in turn influences their
bioavailability (Semete et al., 2010). Moreover, the larger surface to volume
ratio of nanoparticles allows higher drug loading and dissolution rate influencing
the bioavailability (Soppimath et al., 2001; Kondo et al., 1993; Semete et al.,
2010). Additionally, crystallinity of many nanoparticles (e.g. polymers)
significantly affects their degradable speed which influences the biological halflife of associated drugs (Izumikawa et al., 1991; Mahato, 2007).
Secondly, nano-drugs possess comprehensive advantages in context to
the drug release kinetics. The increased specific surface area of nanoparticles
enhances the drug loading ability. Higher amount of drugs in nano-carrier
results in initial burst release and then followed by a constant slow release,
which affect the kinetics and minimize dose frequency (Soppimath et al., 2001;
Kondo et al., 1993). Similarly, crystallinity of materials affects their dissolution
characteristics – the amorphous region degrades faster in compare to
crystalline region. Thus, release kinetics of associated/combined drug is
affected (Izumikawa et al., 1991; Mahato, 2007). Furthermore, surface charge
and hydrophobicity of nanoparticles or coating materials play significant role in
drug kinetics. These properties of nanoparticles greatly affect their molecular
composition and so as their degradation rate is influenced (Semete et al.,
2010). The increased blood circulation time due to hydrophobic coating
prolongs the associated drug release. Also, hydrophilic coating reduces the
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dose frequency of the poor soluble drugs due to their improved solubility
(Blume, 1993; Vert and Domurado, 2000, Immordino et al., 2006).
Third and last, the feasibility of selective targeting can be significantly
improved by the nano-drugs. This, in turn, can improve the drug efficacy and
side effects can be minimized as well. Nano-drugs or nano-carriers can be
molded for both, passive and active targeting. The reduced first pass hepatic
metabolism and increased blood circulation time of nanoparticles makes them
suitable for the purpose of passive targeting. The application of passive
targeting of lymph nodes (Maeda et al., 2000; Mitra et al., 2001; Briz et al.,
2003; Gunaseelan et al., 2010). In active targeting, drugs or carriers are
combined with target efficiency of nanoparticles has been successfully
demonstrated in the case of enhanced permeability and retention effect in
targeting tumors of enterohepatic circuit and HIV infections moieties or vector
molecules that can recognize and bind to a specific target sit. Thus, direct
administration of a drug into an affected organ or tissue can be achieved.
Various substances like antibodies, peptides, hormones, polysaccharides,
lipoproteins, etc can be used as targeting moieties. Thermal- and pH-sensitive
targeting molecules (e.g. N-isopropylacrylamide) and suitable adjuvant can also
be part of active targeting nano-drug carriers (Chung et al., 1998; Kohori et al.,
1998; Meyer et al., 1998; Yoo et al., 2002; Sershen et al., 2000; Liu et al.,
2010).

20

1.5.

Nanomedicines for neuroAIDS treatment:
A complete lack of ARV therapies for ~40% of AIDS patients (WHO, 2012)

and further, ineffectiveness of HAART in treatment of HIV-associated
neurological syndromes has molded the neuroAIDS as a consistent global
problem. In the wake of fact that more than 98% of small and large drugs are
unable to cross the brain barriers (Pardridge, 2007), which is believed to be main
impediment in the cure of neuroAIDS, several strategies are being experimented
to administer the desired therapeutic levels of anti-HIV drugs across those
barriers. Transcranial drug delivery (focused ultrasound and microbubble
approach to disrupt the BBB), transnasal drug delivery (direct access to CNS
from nasal cavity via olfactory neurons and avoid fist-pass metabolism),
disruption of BBB using pharmacological agent (etoposide and cisplatin), hyperosmotic solutions (mannitol and urea), prodrugs approach (lipidization of ARV
molecules and fusion of drugs with cell-penetrating peptides or antibody specific
to BBB receptors), and inhibition of ABC transporters (P-gp) are few approaches
with potential to deliver ARV drug across BBB (Wong et al., 2010; Nair and
Saiyed, 2011). However, these strategies have less strength than limitations
which restrict their use as common and novel drug delivery method. An effective
drug delivery method or diagnostic agent must have systemic administration
ability i.e., majority of therapeutic agents should be delivered to the target site
while non-target site should get minimal drug exposure. Complying with this
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notion, practice of nanotechnology in medicine has shown exciting prospect for
development of novel drug delivery system.
1.6.

Functional

nanovehicles

for

prevention

and

treatment

of

neuroAIDS:
Improved drug delivery across brain barriers is essential for the
management of neuroAIDS. In this context, applications

of various

nanocarriers have generated a promising trend for the better ARV drug
distribution to the CNS. Schemes of CNS drug delivery using nanovehicles can
be broadly classified based on their passive or active targeting ability (Wong et
al., 2010). Approaches involving the passive targeting can result in
accumulation of higher concentration of drug at endothelium of the BBB. This
local gradient difference may allow the drug penetration by passive diffusion.
Also,

trafficking

via

non-receptor

mediated

endocytosis

(e.g.,

macropinocytosis) may enhance the cellular drug uptake. Actively targeted
drug trafficking can be possible via receptor mediated endocytosis when
periphery of nanocarriers is tagged with ligand molecules matching to specific
cell receptor (Pelkmans et al., 2001; Amyere et al., 2002; Kaplan et al., 2005;
Khalil et al., 2006). Nanocarriers can also be tagged/ loaded with specific efflux
transporters inhibitors or blocking agent which can result in increased drug
concentration across the BBB (Liu et al., 2010). Several nanocarrier systems
such as liposomes, dendrimers, different nanoparticles, micelles, etc. have
been intensively explored (Figure 2) and approaches for their improvement are
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under investigation. Recently, applications of magnetic nanocarriers and
monocytes/macrophage based nanoformulations have gained considerable
interest for the treatment of neuroAIDS.
1.6.1. polymeric nanovehicles:
Acrylic and polyester polymers are the most studied synthetic polymeric
compounds as nanocarriers for CNS drug delivery. Poly (butyl cyanoacrylate)
(PBCA), an acrylic polymer, have been extensively explored for this purpose.
PBCA possess rapid in vivo degradation ability which can minimize their longer
accumulation and, in turn, can prevent the brain from potential polymeric
toxicity (Wong et al., 2012). The lipophilic property of PBCA makes it suitable
for loading of various kinds of compounds with hydrophilic property and
weak/low basicity (Alyaudtin et al., 2001; Gao et al., 2006). Without causing
any permanent physical harm to BBB, PBCA nanoparticles are able to deliver
an improved amount of ARV drugs in both brain tissues and CSF. Kuo and
Chen (2006) reported that the use of PBCA nanoparticles enhance the in vitro
BBB permeability of ARV drugs zidovudine and lamivudine by 8–20 and 10–18
fold, respectively. In the same study, application of other acrylic polymer
nanoparticle, methylmethacrylate–sulfopropylmethacrylate (MMSPM), showed
100% rise in the BBB permeability of zidovudine and lamivudine. Additionally,
PBCA and MMPSM coated with PS-80 (a tensoactive agent) were used for the
delivery of ARV drugs, stavudine, delaviridine, and saquinavir, in in vitro BBB
model. It was found that permeability of these three drugs was enhanced by
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~12-16 and 4-11 folds with PBCA and MMSPM formulations respectively (Kuo
and Su, 2007). Increase in the BBB permeability of acrylic polymers are
facilitated by receptor mediated transcytosis which is triggered by binding of
apolipoproteins (adsorbed on the surface of polymeric nanoparticles) to the low
density lipoprotein receptors on BMVECs (Kim et al., 2007). Besides this
transcellular pathway, acrylic polymers can also use the paracellular route via
reversible disruption of BBB for short period of time (Alyaudtin et al., 2001;
Rempe et al., 2011).

Figure 2: Nanoparticles used for the delivery of ARV drugs across BBB. (A) Polymeric
nanoparticle. (B) Dendrimer nanoparticle. (C) Polymeric micelle. (D) Nonpolymeric micelle. (E)
Liposomes. (F). Solid lipid nanoparticles. (G). Lipid nanoemulsions. (H) Lipid nanocapsules.
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Despite these merits, application of polymeric nanoparticles is restricted
because they are not ideal for the delivery of polar/ionic compounds (Wong et
al., 2010). Furthermore, process of PBCA degradation can produce toxic
formaldehyde by-products (Olivier, 2005). Thus, other polymers like polyesters
are considered a safer choice for CNS drug delivery. Two polyester, polylactide
(PLA) and poly(lactide-co-glycolide) (PLGA) have been approved by United
States Food and Drug Administration for human use (D’Souza and DeLuca,
2006). These highly versatile biocompatible polyesters are degraded into
glycolic acid and lactic acid which are converted into water and carbon dioxide
via TCA cycle and eventually eliminated from the body (Yoo et al., 2005;
Makadia and Siegel, 2011). Importantly, injection of these polyesters induces
negligible and transient inflammatory response (Athanasiou et al., 1995; DechyCabaret et al., 2004). Variety of drugs of both hydrophilic and hydrophobic
nature can be entrapped on the matrix of PLA and PLGA. In addition, drugs
entrapment can be tailored for sustained release for longer time (Zhang and
Feng, 2006). Surface modifications of these polyester polymers such as
PEGlyation (attachment of poly(ethylene glycol), agglutinin coating, alginate
embedding, etc., have been strongly recommended for delivery of therapeutic
dose across the BBB. Both, PLA and PLGA with certain modifications have
been shown to be useful for the improved brain delivery of many non-ARV
drugs such as dexamethasone, vasoactive intestinal peptide, superoxide
dismutase, etc (Kim and Martin., 2006; Gao et al., 2007; Reddy et al., 2009; Liu
et al., 2012). Study on ARV drugs by Destache et al., (2010) demonstrated that
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nanoformulations of ritonavir, lopinavir, and efavirenz with PLGA can maintain a
sustain peak of about 28 days in mice brain which is limited to only 2 days with
free drugs. Similarly, Rao et al., (2008) demonstrated that at two weeks postadministration, PLA nanoparticles in conjugation with Tat peptides could result
in 800 fold higher level of ritonavir in mouse brain in compare to drug delivered
in solution. It should be noted that the cell penetration ability of Tat peptide
makes it a natural accessory for carriers used for drug delivery across BBB.
Along with synthetic polymers, natural polymers such as albumin, chitosan,
alginate, gelatin, collagen, etc. are also being explored as the potential
nanocarrier for brain drug delivery (Semete et al., 2010). Al-Ghananeem et al
(2010) investigated the potential of chitosan for delivery of ARV drugs via both,
intravenous and intranasal route and found a significant improvement in the
level of didanosine in brain and CSF of rat.
1.6.2. Dendrimer nanovehicles:
Dendrimers are basically globular or spheroidal structures made up of
controlled repeats of monomer units branched around a central core (Figure
2B) (Svenson et al., 2009; Wong et al., 2010). They can be engineered in the
size range of 10-100 nm and may contain many reactive functional end groups,
which make them potent for drug delivery systems (Semete et al., 2010).
Dendrimers may also contain internal void spaces. Thus, both encapsulation (in
void space) and conjugation (with reactive end groups) of compounds with
different polarity can be possible with dendrimers. Though more than 100 types
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of dendrimers exist, five main classes used for medicinal purposes are:
Polyamine amine, Polypropyleneimine (PPI), Phosphorus, Carbosilane, and
Polylysine dendrimers. However, Phosphorus dendrimers has never been used
for HIV research (Dzmitruk et al., 2011). Similar to polymeric nanoparticles,
dendrimers have been mostly studied for brain delivery of anti-cancerous drug.
Nevertheless, Jiménez et al., (2010) investigated the potential of 2G-NN16
dendrimers (a Carbosilane dendrimer) in in vitro BBB model for delivery of
antiviral (HIV) siRNA. This siRNA/2G-NN16 dendriplexes showed permeability
across the in vitro BBB and caused a significant reduction in the viral
replication. Most of the ARV study involving dendrimers in HIV research has
been restricted to different cell types such as, macrophages, dendritic cells,
MT2 cells, etc (Dutta and Jain, 2007; Dzmitruk et al., 2011) and thus, more in
vitro and in vivo BBB investigations are required before their use for CNS
delivery of ARV drugs. The limited application of dendrimers can be attributed
to their complex synthesis process and inconsistent and premature drug
release kinetics (Wong et al., 2010). The drug release mechanism is also not
clear, though some report suggest toward transcytosis through the BBB
(Dzmitruk et al., 2011). Additionally, polycationic surface groups of dendrimers
proved to be toxic for negatively charged cell membranes resulting in cell death
(Bawarski et al., 2008; Pion et al., 2010).
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1.6.3. Micelles nanovehicles:
Micelles are self-aggregated assembly of amphiphilic molecules
dispersed in aqueous media (Kabanov and Alakhov, 2002; Wong et al., 2006).
The diameter of micelle particles may vary from 1-50 nm (Semete et al., 2010).
Particles are assembled in such a way that there is an inner hydrophobic core
and the hydrophilic heads of amphiphilic molecules are exposed outside (Figure
2C and D). The inner core serves as the encapsulation space competent for the
better solubilization of poor water-soluble and lipophilic compounds (Jones and
Leroux, 1999; Gaucher et al., 2005; Bae and Kataoka., 2009; Wong et al.,
2010). Three types of amphiphilic molecules, namely, block-copolymers,
surfactants and polymer-lipid conjugates are used for formation of micelles
(Trivedi and Kompella, 2011). However, pluronic block-copolymers has been
the most studied micelles types for CNS drug delivery. Pluronic micelles
demonstrate zero toxicity to the BBB and can inhibit efflux transporters such as
P-gp, MDR1, etc which, in turn, increase their substrate permeability (Batrokova
et al., 2003; Spitzenberger et al., 2007; Shaik et al., 2008). Notably, many ARV
drugs are substrates for efflux transporters/receptors of BBB. Thus, pluronic
micelles can serve as both, drug carrier and efflux inhibitor and have been
demonstrated to be valuable for CNS delivery of ARV drugs. Batrokova et al
(1999) showed that exposure of pluronic P85 enhance permeability of ritonavir
across in vitro BBB. Similarly, in vivo experiment by Spitzenberger et al (2007)
demonstrated that administration of pluronic P85 alone or in combination with
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ART (zidovudine, lamivudine, and nelfinavir) resulted in 78-92% reduction in the
p24 expressing monocyte-derived macrophages (MDM) from mouse brain in
compare to 62 % of only ART treated group at two weeks post-inoculation of
HIV. Additionally, Sharma and Garg (2010) suggested that micelles may be
tailored for highly selective active targeting by tethering hydrophilic block to
ligands specific to HIV reservoir receptors such as lecitn. Nevertheless,
instability of the non-cross-linked pluronic micelles remains a matter of concern
because it may reduce the circulation time resulting in premature drug release
(Trivedi and Kompella, 2010).
1.6.4. Liposomes nanovehicles:
Liposomes are the first and probably the most applied drug delivery
carrier (Langer, 1976; Costantino et al., 2009; Wong et al., 2012). They can be
defined as auto-spontaneously arranged unilamellar or multilamellar, spherically
closed colloidal vesicles made up of amphipathic phospholipid bilayer
membranes surrounding an aqueous core. While one hydrophilic head of
phospholipid bilayer is exposed to outside, the other is in contact with vesicle
core (Figure 2E). Thus, hydrophobic group of the bilayer is protected from the
aqueous environment. This unique character of liposomes allows loading of
both hydrophilic (encapsulated in aqueous core) and hydrophobic/lipophilic
(incorporated into the bilayer of phospholipid) compounds (Sharma & Sharma,
1997; Voinea et al., 2002; Carvalho et al., 2011). Depending upon the
processing methods and constituent, size of liposomes may go up to mm;
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however, it can be restricted to a minimum of 20-30 nm which is ideal for a
nanocarrier (Wong et al., 2010). Surface of liposomes can be engineered for
active targeting by applying surface charge modifications (Makino and Shibata,
2006) and/or conjugation of antibodies/ligands specific to diseased cells or
tissues including brain and CNS (Desormeaux and Bergeron, 1998; Allen et al,
2002; Kreuter, 2004). Additionally, modifications such as PEGlyation can
improve the inherent poor stability of conventional liposomes (Koukourakis et
al., 2000; Jain, 2008; Bertrand et al., 2010) and can also reduce their uptake by
reticuloendothelial system resulting in improved plasma circulation time
(Gunaseelan et al., 2010). Lipid composition may also be tweaked for better
stability and circulation rate (Vitas et al., 1996; Katragadda et al., 2000).
Different types of liposomes used so far for the delivery of anti-HIV/AIDS drugs
can be broadly categorized into ionic-, immune- and sterically-stabilizedliposomes (Lanao et al., 2007). The rationale of using liposomes for ARV drugs
is based on the fact that mononuclear phagocytic system recognizes
conventional liposome as foreign body; and since monocytes and macrophages
are HIV reservoirs and can travel to brain, an improved efficacy of drugs can be
achieved (Prior et al., 2002). Kim et al., (1990) demonstrated that half-life of
intraventricularly administered, liposome-encapsulated zalcitabine in the brain
of Sprague-Dawley rat increase to 23 h as compared with 1.1 h for the
unencapsulated drug. In the same line, Dusserre et al., (1995) showed that
liposomal encapsulation could enrich the rat brain with about 13 times more
foscarnet – a salvage therapy for multi-drug resistant AIDS patients – in
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compare to its solution. Further, the superiority of CNS targeting ability of
liposomes-loaded AZT-myristate (prodrug of AZT) was studied by Jin et al
(2005). It was shown that, with about 98% encapsulation efficiency and longer
half-life, a higher concentration of AZT was found in the brain and other organs
of rats. Potential of liposomes have also been evaluated for management of
HIV-related opportunistic infections which is critical for the HIV/AIDS patients.
Several fold increase in the concentration of amphotericin B (drug for fungal
infections in HIV patients) was demonstrated when liposomes tethered with
RMP-7 (Bradykinin B2 receptor agonist) were used for delivery across in vitro
rat-BBB model (Zhang et al., 2003). Despite these demonstrations of potential
of liposomes for improving ARV drug delivery, stability and leakiness of loaded
drug during storage remain the issue to be sorted out (Semete et al., 2010).
Additionally, low drug entrapment ability, especially for water-soluble drugs due
to tiny space of aqueous core (Torchilin, 2005), is an area for improvement in
liposome-based drug delivery.
1.6.5. Solid lipid nanoparticles (SLN) based nanovehicles:
Recently, SLN (Figure 2F) has emerged as novel particulate system with
tremendous potential to be used as a drug delivery nanocarrier. For the
synthesis of SLN, one or more biocompatible solid lipids such as fatty acids,
glycerides, waxes, glycerine mixtures, etc. are liquefied by heating and
dispersed and stabilized in either ionic or non-ionic surfactant which can be
emulsifiers and/or co-emulsifiers (Gupta & Jain, 2010; Carvalho et al., 2011).
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The size of resulting solid lipid particles may vary from 1 to 1000 nm and are
compatible for carrying both hydrophilic and lipophilic drugs (Gupta and Jain,
2010). Because of the lesser non-specific cell toxicity, superior physical and
biological stability, high tolerability, higher drug entrapment efficacy, and costeffective manufacturization, the SLN is believed to be a better nano-drug carrier
than other colloidal carriers such as liposomes, PLGA, etc. (Muller et al., 1997;
Mehnert and Mader, 2001; Reddy et al., 2006; Wong et al., 2010). Additionally,
flexibility to modify its size and charge can be employed for the site-specific
targeting and for drug release in response to specific stimuli such as
temperature, pH, etc (Bummer, 2004; Manjunath et al., 2005). Also, the
immediate burst drug release profile of conventional SLN (attributable to their
larger surface area) can be modified for prolonged drug release (Semete et al.,
2010).

All these properties in conjugation with the natural ability of small

lipophilic material to cross the BBB make SLN a favorable nanocarrier for the
CNS drug delivery. In this context, few studies have shown the potential
applicability of SLN for ARV drug delivery across BBB. Kuo and Su (2007) used
in vitro BBB model of human BMECs and demonstrated that the permeability
coefficient of stavudine, delaviridine and saquinavir loaded on SLN was
respectively 4–5, 8–11 and 9–11 times as compared with free drugs. In the
same study, delaviridine and saquinavir loaded on SLN showed enhanced
permeability than those loaded on MMSPM; however, it was suggested that the
particle size of these nanoparticles may have significant influence on their drug
-loading, -entrapment and BBB permeability efficacy. Further, the same group
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(Kuo and Kuo, 2008) performed that under the influence of 5mV
electromagnetic force (EMF) the in vitro BBB permeability of SLN loaded
saquinavir was better than that loaded on PBCA and MMSPM; thus, a
combination therapy, involving SLN with EMF, was recommended for the
beneficial clinical application. Other in vitro BBB model study by Chattopadhyay
et al (2008) showed a significantly improved cellular uptake of SLN loaded
atazanavir in compare to aqueous solution. Similarly, higher cellular
accumulation of Rhodamine-123, a substrate of efflux transporter P-gp, was
also shown in this study. Thus, it was predicted that SLN may either mask or
bypass the efflux pump. Despite these early promising in vitro data, supportive
in vivo experiments are yet to be tested. Thus, more in vitro and in vivo study
are necessary to delineate the authenticity of SLN for the delivery of ARV drugs
in brain.
1.6.6. Magnetic nanovehicles:
Magnetite (Fe3O4) and maghemite (Y-Fe2O3) are the most commonly
used magnetic nanoparticles (MNPs) in the field of biomedicine (Chomoucka et
al., 2010; Yoo et al., 2012). They have been extensively investigated for targetspecific improved drug delivery. The main advantage that makes MNP superior
over other counterparts such as liposomes, micelles, polymeric nanoparticles,
etc. is that the unique superparamagnetism property can be utilized for
simultaneous monitoring and quantitation of their tissue-specific or nonspecific
distribution (Jain et al., 2008). Thus, techniques like magnetic resonance

33

imaging (MRI) and magnetometery can be applied for, though indirect,
measurement of localization of MNPs associated drugs (Koning et al., 2007)
which may help in determining site-specific optimal or suboptimal dosing.
Besides, MNPs possess many characteristics essential for a suitable drug
delivery nanocarrier. First, synthesis of MNPs is quite easy (Wiogo et al., 2012)
and it is feasible to produce monodispersed particles at the laboratory. Second,
the flexibility in the size of MNPs, ranging from a few up to tens of nanometers,
gives opportunity for optimization of sizes as per requirement of the study. It
should be noted that the higher surface to volume ratio enhances target-affinity
of MNPs in comparison to the micro-sized magnetic particles and can even
manipulate and target at the subcellular organelles levels. Third, MNPs can
respond to an external magnetic field. Thus, it is possible to “remote control” the
movement of drug loaded nanoparticles for target-specific delivery by applying
the magnetic force at the exterior of desired site (Pan et al., 2012). Fourth, as
mentioned above, the MNPs can function as contrast agent for MRI because
signal of protons, an essential requirement for MRI, in the periphery of particles
is enhanced by the magnetic moment (Chaughule et al., 2012). Fifth, aqueous
solutions of MNPs such as Fe3O4 perform amphoterism and develop positive or
negative charges at the magnetite-water interface in pH-dependent manner
(Tombacz et al., 2006;). The flexibility in the surface charge allow binding of
wide range of molecules either via direct, but week, ionic interactions to the
MNPs (Saiyed et al., 2009) or via surface coating or tethering agents (Yoo et
al., 2012; Amal et al., 2012). The well-defined and rigid structures of MNPs, with
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or without coating, further widen the attachment options by acting as a solid
binding platform for various ligands (Pan et al., 2012). Sixth, in combination with
the liposomes, MNPs can also be developed as hybrid nanoparticles called
“magnetoliposomes” (Figure 3).

Figure 3: Magnetic Nanoparticles based nanovehicles: Magnetoliposome for drug delivery across
BBB.

The liposomal encapsulation of MNP is advantageous in many ways.
While drugs attached with MNPs can be encapsulated in the liposomal core,
additional free drugs can be supplemented on the phospholipid bilayers and
core as well. Thus, per unit loading efficiency of nanocarrier is enhanced. Also,
the liposomal encapsulation protects the drug loaded on the MNPs from the
biological degradations and increase the circulation time resulting in increased
bioavailability. Furthermore, magnetoliposomes can be utilized for the
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monocytes/macrophage-based nanodrug delivery at the various inflammatory
sites including the brain (Jain et al., 2003; Saiyed et al., 2010). The movement
of magnetoliposomes or magnetized monocytes/macrophages for targeted drug
delivery can be manipulated in the same way as for naked MNPs. Seventh,
doses of MNPs within the permissible limit have non-significant safety concerns
and are biodegradable (Jain et al., 2008). Particularly, it has been suggested
that biologically produced nanosized magnetosomes from magnetotactic
bacteria, which is predicted to be highly biocompatible, can be utilized in the
same way as artificially synthesized MNPs (Lefevre et al., 2011; Sun et al.,
2011). Thus, we see that MNPs possess many features required to be molded
for nano-drug delivery in target-specific manner.
1.6.7. Cell-based nanovehicles:
The

inherent

migratory

potential

of

inflammatory-response

cells

(monocytes, macrophages, dendritic cells, neutrophils, lymphocytes, neuronal
stem cells, bone-marrow derived mesenchymal stromal cells, etc) towards the
zone of inflammation can be exploited for the targeted drug delivery (Batrakova
et al., 2011). Although still at the preliminary stage, this relatively newly
hypothesized drug delivery strategy own superior therapeutic and diagnostic
potential. While cells can be genetically modified for a continuous production of
therapeutic molecules (Studeny et al., 2002; Muller et al., 2006; Menon et al.,
2009), in the context of nanomedicine, drug loaded nanocarriers such as
liposomes, magnetoliposomes, polymers, etc are either packaged inside the
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cell or, in extreme case, attached to the cell surface for the delivery at the
specific injury site (Behr et al., 1997; Krantz et al., 1997; Thiele et al., 2003;
Nowacek et al., 2009; Cheng et al., 2010; Zhao et al., 2011; Nair and Saiyed,
2011; Roy et al., 2011). Entry of drug loaded nanovehicles in these cells is
mediated by cell surface receptors such as mannose, complement, Fc
receptors, etc. Thus, coating of nanocarriers with the receptor-specific moieties
such as mannose, folate, gelatin, A- protein, RGD peptide, etc complement the
recognition by specific cell surface receptors leading to cellular internalization
(Batrakova et al., 2011). Factors such as surface charge, size, and shape of
nanocarriers also plays vital role in their internalization by cells. For example, it
has been demonstrated that absorption of positively-charged nanoparticles by
cells is better than their opposite counterparts (Nowacek et al., 2009). At the
same time, the drug preservation efficiency of positively-charged nanoparticles
in the cell is also superior (Thiele et al., 2003; Zhao et al., 2011). Once inside
the cell, it is critical to home the drug-loaded cell-carriers at the right site. To this
end, monocytes and macrophages have gained considerable attention for
delivery of drug across the CNS (Dou et al., 2006; 2009; Muthana et al., 2008).
These immunocytes possess margination and extravasation properties and can
cross the BBB paracellularly in response to brain inflammation (Pawlowskiet al.,
1988; Lossinsky et al., 2004). Thus, “Trojan nanocarriers” residing inside these
cells can be delivered in the brain (Figure 4). Uploading of drugs from cellular
carriers at the delivered site is an area which is less understood and need to be
intensively investigated for advancement of this novel delivery system. In this
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context, it is believed that feasibility of controlled drug release from cellular
carriers may significantly rely on prolonged stay of cell-carriers at the target site,
pathology-specific response (change in temperature, pH, etc), exocytosis of
drug containing intracellular vesicles, and intracellular Ca2+ concentration of
carrier cells (Sollner et al., 1993; Batrakova et al., 2007; 2011). Additionally,
external stimulus such as mild hyperthermia may also affect the drug uploading
from cell-carriers as has been shown for anti-cancer therapy (Ikehara et al.,
2006). Other area which must be addressed for better practicality of cellmediated nanocarriers is the minimization of possible cytotoxicity. Mononuclear
phagocytes recruited in response to inflammatory cytokines produce reactive
oxygen

species.

In

the

same

line,

inhibition

of

recruitment

of

monocytes/macrophages in the zone of inflammation is part of therapeutic
strategies for many neurodegenerative disorders (Hendriks et al., 2005).
Nonetheless, few reported studies to date indicate no shed of cytotoxicity in
macrophage-mediated drug delivery in the brain (Brynskikh et al., 2010).
Eventually, successful clinical application of this method will depend upon
loading of nanoformulated drugs either to harvested mononuclear phagocytes
from peripheral blood or to artificially differentiated monocytes from harvested
stem cells from bone marrow and their re-infusion/infusion to patients
(Batrakova

et

al.,

2011).

Injection

of

nanoformulations,

coated

with

monocytes/macrophages specific receptors, in blood circulation may also be
another way for development of cell based delivery in clinical settings
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(Bestman-Smith et al, 2000). However, sufficient research-homework is
required before practical application of these speculations.

Figure 4: Cell-based drug delivery: Monocytes/Macrophages loaded with liposomal nanocarriers.

Cell mediated delivery of nanoformulated drugs is gaining significant
consideration for the treatment of various brain diseases, specifically in chronic
pathologies such as Alzheimer’s, Parkinson’s, brain cancer, epilepsy, etc
(Popescu et al., 2006; Batrakova et al., 2007; Boison et al., 2009; Garcia et al.,
2010; ). Its implications in HIV related neuropathogenesis has also shown
encouraging trends. Dou et al., (2009) demonstrated that macrophage-based
nanoparticle platform can successfully deliver the active ARV drug in the brain.
Indinavir formulated in suspensions of lipid nanocrystals were packaged into ex
vivo cultivated bone-marrow-derived macrophages and injected intravenously
into severely combined immunodeficient HIV-1 encephalitis (HIVE) mice. High
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drug release in different regions of the brain were noticed consistently for at
least two weeks and corresponding reduction in HIV replication were observed
in the HIVE brain regions.

In the same line, Nowacek et al., (2010)

nanoformulated a combination of atazanavir, efavirenz, and ritonavir in a
mixture of block copolymers and liposomes and loaded into MDM. In vitro drug
release study demonstrated their continuous presence from minimum of 15
days to more than 20 days with complete suppression of viral infection. Basic of
this study was recently expanded with another nanoformulated combination of
atazanavir, ritonavir, indinavir, and efavirenz. By co-cultivating the drugspacked mononuclear phagocytes with human brain microvascular endothelial
cells, it was suggested that intracellular crosstalk may facilitate transfer of drugs
from carrier/donor cells to recipient cells (Kanmogne et al., 2012). However,
mechanisms of this cell-to-cell transfer have not been explained.
1.6.8. Other promising nanovehicles for ARV drug delivery across BBB:
The growing popularity of nanotechnology in recent years has steadily
opened the field for variety of nanomaterials. With the same perspective, many
nanocarriers have been explored for their possible application in the field of
nanomedicine. Two novel polymeric materials, nanoemulsions and lipid
nanocapsules (LNC) (Figure 2G and H), have been preliminarily investigated for
their ability to deliver ARV drugs in brain. Vyas et al., (2008) demonstrated that
the oral administration of saquinavir loaded oil-in-water nanoemulsions to
Balb/c mice improved the brain uptake in compare to the aqueous formulation.
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It was suggested that higher availability of drug in the brain may be result of the
higher rate of absorption of drug encapsulated in nanoemulsions. Potential of
other polymeric novel nanoparticles, LNC, for the delivery of ARV protease
inhibitor (Indinavir) in the mouse brain was evaluated by Pereira et al., (2005). It
was found that tissue/plasma ratios of LNC loaded Indinavir in the brain of
normal (mdr1a+/+) or efflux transporter, P-gp deficient (mdr1a-/-) mouse
increased by 1.9 times on average as compared with Indinavir in aqueous
solution. At the same time, ratio of aqueous Indinavir in the brain of mdr1a-/mouse was 21.3-fold higher than mdr1a+/+ mice suggesting that mechanisms
other than, or additional to, P-gp inhibition may influence the higher uptake of
LNC loaded drugs.
Few other nanocarriers such as gold nanoparticles (Bowman et al, 2008;
Reynolds et al, 2012a; 2012b; Arnaiz et al, 2012), silver nanoparticles
(Elechiguerra et al, 2005; Lara et al, 2010 & 2011), aptamers (Neff et al, 2011;
Zhou and Rossi, 2011; et al, 2011; Ramalingam et al, 2011), carbon nanotubes
(Liu et al, 2007; Cheng et al, 2010), quantum dots (Bonoiu et al, 2009), etc.
have also been explored either for their modulated antiretroviral activity or for
the targeted drug delivery in the field of HIV research. However, these initial
applications are either restricted to different HIV10-infected cell types or their
applicability in ARV drug delivery across CNS have been derived from other
brain related, but directly or indirectly connected to HIV research such as drug
of abuse, integrity of BBB, etc. Hence, further in vitro and/or in vivo
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investigations can shed light on the legitimacy of their application for ARV drug
delivery in CNS.
1.7.

Nanovehicles mediated delivery of anti-abuse drugs for treatment of
neuroAIDS:
Drug addicted AIDS patients account for one-tenth of HIV-infected

individuals. Addiction of abusive drugs remarkably affects the initiation of HIV
infections and expedites the progression of associated pathogenesis.
Particularly, neuroimmunological changes as a consequence of alterations in
reward or relapse pathways associated with drug abuse (Coller and
Hutchinson, 2012) significantly enhance the progression of neuropathogenesis
during HIV infections (Nath et al., 2002; Burdo et al., 2006; Hauser et al., 2007;
Ferris et al., 2008; Rogers, 2011). Towards this end, last two decades of
systematic research on molecular mechanism for addiction therapy emphasize
on use of antagonists against different neuronal and non-neuronal receptors
involved in the signaling cascades induced by drugs of abuse such as
dopamine receptor antagonist, opioid-antagonist, etc. (Xi et al, 2006;
Shippenberg, 2009; Gerra et al, 2009; Peng et al, 2010; Karila et al, 2011; Zhu
et al, 2011; Bonoiu et al, 2009; Coller and Hutchinson, 2012). Nevertheless,
majority of drug formulations tested so far in the pre-clinical or clinical
experimental settings for treatment of neuroAIDS is restricted to the ARV drugs
only. Antiretroviral (ARV) drugs are meant to target HIV replication and have
little

or

no

effect

on

the

HIV-associated
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neuronal

disorder.

Thus,

supplementation of anti-dependence agents with ARV drugs in the treatment
regimen of drug addicted individuals at very early post-diagnosis of HIV
infection may countercheck the rate of concerted neurotoxicity and disease
progression by attenuating the rewarding effects of drug abuse.
The application of nanocarriers for target-specific drug delivery may be
extended to all sorts of drugs and diseases. This approach has just commenced
for addiction therapy (Bonoiu et al, 2009) and attenuation of concomitant
deleterious effects of drug abuse and HIV infection. Only recently, Reynolds et
al (2012) reported application of gold nanoparticles mediated delivery of siRNA
against galectin-1 (an adhesion molecule) in methamphetamine treated, HIV
infected MDM. They showed that stimulatory effect of methamphetamine on
gelatin-1 gene expression is countered due to siRNA knock down and
concomitantly HIV infection is attenuated. However, any similar nanocarriers
based study to counter the concerted neurodegenerative effect of abusive
drugs during HIV infection is completely lacking. Thus, in our views,
nanocarriers based in vitro and in vivo study must be initiated to deliver various
anti-dependence agents across the BBB and subsequently the legitimacy of
their use for drug abuse associated neuropathogenesis during HIV infections
could be delineated. Moreover, transfer of this strategy in clinical settings may
be beneficial for suppression of rate of pathogenesis in drug addicted HIV
patients and, in turn, it may add to achieve near-normal life expectancy for
treated individuals.
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1.8.

Future perspectives:
Reduction or elimination of HIV load from their safe sanctuaries such as

brain still remains the major limitation for treatment of this pandemic. To this end,
nanomedicines have shown tremendous promise and various forms of
nanovehicles are in pre-clinical stage for targeted delivery of ARV drugs to the
drug-impenetrable viral sanctuaries. Thus, relevant research-homework has to
be elucidated more rigorously to sort out the various associated shortcomings of
this novel approach in treatment of neuroAIDS. Better structural and
physiological understanding of the brain barriers, selection of safe (non-toxic and
biodegradable) material for the nanovehicles, development of specific brain celltypes

targeting

strategies,

refinement

of

multifunctional

nanocarriers,

development of on-demand drug release strategies, universal formulation
schemes for intramuscular, intravenous or oral delivery, and more realistic in vivo
experimentations are few areas which should be given importance to enhance
the feasibility of nanodrugs to treat the AIDS related neuropathogenesis.
Additionally, delivery of neuron-resuscitating agents such as exogenous
neurotrophins to the affected brain may improve the survival, development and
function of neurons. Furthermore, special attention should be given to generation
of new strain of resistant virus while using the nanodrugs treatment. Eventually,
proper pharmacokinetic and pharmacodynamics studies and large scale
manufacturization will shed light for successful application of nanodrugs in more
realistic clinical settings, impacting the live of HIV infected patients.
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2. Hypothesis and aims
Practice of nanotechnology in medicine has shown exciting prospect for
development of a novel drug delivery system to administer the desired
therapeutic levels across the BBB. Several nanocarrier systems such as
dendrimers, polymeric nanoparticles, micelles, etc have been intensively
explored (Wong et al., 2010; 2012). Nevertheless, these nano drug-delivery
methods have one or other major limitations that affect the bioavailability of
desired amount of drugs at the targeted site. As such, more than 99% of the
nanodrugs/carriers are deposited either in liver, lungs, or other lymphoid organ
before they may cross BBB (Gunaseelan et al., 2010). Additionally, poorlyunderstood and ambiguous mechanistic details behind the delivery of existing
nanocarriers across the BBB are prohibiting their advancement as brain-specific
nanodelivery system. So, a fast and effective way of delivering and releasing the
drugs from the carrier in the brain is very much needed to eradicate HIV
reservoir. More recently, the use of magnetic nanoparticles, particularly
magnetite (Fe3O4), has attracted significant importance in biomedical applications
(Chomoucka et al., 2010; Yoo, 2012). Magnetically guided drug targeting has
been successfully demonstrated in various pathological cases including
carcinomas, inflammations, etc (Senyei et al., 1978; Chertok et al., 2008;
Escribano et al., 2011). However, its application in the field of HIV/AIDS is
limited. We explored the potential of magnetite for delivery of CTOP, BDNF and
AZTTP in brain and found that functional efficacy of MNP bound drug remains
comparable to the free drug. Hence, it is postulated that ARV and anti-abuse
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drugs may be directly immobilized on the surface of MNPs (Fe3O4) via ionic
interaction and under the influence of external magnetic force MNPs based
nanoformulations can be delivered across the blood-brain barrier (BBB) in more
effective manner leading the way for treatment of HIV and associated
neurotoxicity. Accordingly, following aims are proposed:
Aim 1: To characterize binding isotherm and pharmacokinetics of MNP bound
anti-opioid and neuroprotective agent and ARV drugs.
Hypothesis: (a) Aqueous solutions of MNPs perform amphoterism and develop
positive or negative charges at the magnetite-water interface in pH-dependent
manner. Charge on the surface of magnetic particles can allow either week or
strong interaction of ARV and anti-opioid agents. (b) AZTTP is an established
ARV drugs that have inadequate or zero reachability across the BBB under
normal condition. Similarly, CTOP and BDNF cannot cross the BBB. (c) Drugs
bound to MNPs may sustain its biological activity and efficacy may remain
comparable to free drugs.
Aim 2: Development of liposome-based magnetic nanocarriers.
Hypothesis: (a) Encapsulation of MNPs within the core of liposomes will lead to
formation of magnetoliposomes which could be a very promising material for
clinical applications because it remarkably improves the drug stability and
bioavailability in circulation. (b) Magnetoliposomes can be transported across
BBB under influence of external magnetic force. (c) The hybrid form of MNPs
(magnetoliposomes) can reduce the decomposition of drugs due to metabolic
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(enzymztic mainly) activity of peripheral circulation (blood), and clearance and
entrapment by reticuloendothelial systems.
Aim 3: To evaluate the transmigration efficacy of MNP with or without drugs
across the in vitro BBB model and determination BBB integrity.
Hypothesis: (a) MNPs guided nanocarriers may offer potential lead for delivery of
ARV drugs across BBB by application of an external magnetic force which, in
turn, can inhibit viral replication in the CNS. Similarly, CTOP and BDNF should
antagonize the neurotoxic effect of morphine (b) CNS specific homeostasis such
as change in temperature, pH, etc. may trigger the drug release from MNPs. (c)
Due to non-invasive nature of magnetic force, integrity of BBB will remain intact.
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3. Materials and Experimental approaches
3.1. Materials:
Iron (III) chloride (FeCl3, Cat#: 451649), sodium sulfite (Na2SO3, Cat#:
71989), hydrochloric acid (HCl, Cat#: 320331), Ammonium thiocyanate
(NH4SCN, Cat#: 431354), ammonium persulfate ((NH4)2S2O8, Cat#: 248614),
ammonium hydroxide solution (NH3.H2O, Cat#: 320145), and Transferrin (Cat#:
T4132) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Unless
notified, water used for all reactions was HPLC grade. Egg phosphatidylcholine
(EPC, Cat#: 830071P), 1,2-distearoyl-sn-glycero-3-phosphoethnol- amine-N[methyoxy(polyethylene glycol)-2000] (mPEG2000-DSPE, Cat#: 880128P), 1,2distearoyl-sn-glycero-3-phosphoethnolamine-N-carboxylfluorescein (CFPE, Cat#:
810332), and cholesterol (Chol, Cat#: 700000P) were obtained from Avanti Polar
Lipids (Alabaster, AL, USA). The tetrazolium compound [3-(4, 5-dimethyl thiazol2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt
(MTS, Cat#: G3580) was purchased from Promega Corporation (Fitchburg, WI,
USA). Human brain endothelial cell (HMBVEC, Cat#: 1000), human brain
astrocytes (HA, Cat#: 1800) and their culture medium (Cat#: 1001 and 1801
respectively) were brought from ScienCell Research Laboratories (Carlsbad, CA,
USA).

3.2. Synthesis of magnetic nanoparticles:
Magnetic nanoparticles were prepared by co-precipitating of Fe2+ and Fe3+
ions in alkaline solution and treating under hydrothermal condition as described
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earlier (Saiyed et al., 2007). Hundred millilitres solution of 1 M FeSO4·7H2O and
2M FeCl3 (Sigma) were thoroughly mixed and added to 8 M ammonium
hydroxide (Sigma) with constant stirring at 25°C. The resultant black magnetite
particles were washed repeatedly with hot distilled water to remove impurity ions
such as chlorides and sulphates and dispersed in Tris-EDTA buffer (pH 7.5). The
yield of precipitated magnetic nanoparticles was determined by removing known
aliquots of the suspension and drying to a constant mass in an oven at 60 °C.
Finally, the particles were dispersed in TE buffer at a suspension concentration
of 10 mg/ml. The particles were characterized for size using transmission
electron microscopy (TEM).

3.3. Characterization of MNPs:
3.3.1. X-ray diffraction (XRD) and transmission electron microscopy (TEM)
analysis:
Structural conformation of MNPs was determined by Shimadzu XRD-7000
diffractometer (Shimazdu, Tokyo, Japan). TEM of MNPs was performed with the
Phillips CM-200 200 kV transmission electron microscope operated at 80 kV. A
drop of MNPs was spread on carbon support film on 400 mesh Cu grids (Type B,
Ted Pella, Inc., USA). For better contrast during TEM imaging, samples on grid
were negatively stained with phosphotungstic acid (2.0% w/v; pH 6.4) and dried
at room temperature.
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3.3.2. Particle size and zeta potential
The

hydrodynamic

radius,

size

distribution,

and

surface

charge

measurement of MNPs were carried out at 250C in dynamic laser scattering
(DLS) (90 Plus Particles Size Analyzer, Brookhaven Instrument Corp., USA).
Samples were prepared by diluting equal quantity of magnetic particles in
different pH range of Tris-HCL and Tris-EDTA buffer.
3.3.3. Superparamagnetism measurement
The measurement of superparamagnetism was carried out by classical
vibrating sample magnetometer (Model 4HF VSM, USA). The magnetic
hysteresis loops of the Fe3O4 particles were measured between +1200 to − 1200
Oersted (Oe) at room temperature.

3.4. Binding of drugs onto the magnetic nanoparticles:
3.4.1. CTOP binding to magnetic nanoparticles:
Mixture of MNPs and CTOP procured from Sigma Aldrich at different mole
ratios (1:0.16, 1:0.33, 1:0.66, 1:1, and 1:1.33) were incubated in tube rotator at
room temperature and supernatant were collected for quantification of unbound
CTOP by HPLC. The difference between the total CTOP added and unbound
CTOP was used to calculate the amount of CTOP bound to the MNPs.
3.4.1.1. High-performance
(HPLC/PDA):

liquid

chromatography/Photo

diode

array

HPLC/PDA analyses were performed with a P4000 Thermo-Finnigan
chromatograph (Thermo Electron Corporation, San Jose, California) and
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consisted of a SpectraSystem SMC1000 solvent delivery system, vacuum
membrane degasser, P4000 gradient pumps and AS3000 autosampler. Column
effluent was monitored at 254 nm with a SpectraSystem UV6000LP variable
wavelength PDA detector and ChromQuest 4.1 software. Analytical separations
were carried out with a C18 RP Hypersil GOLD column (RP5, 250 x 4.6 mm, pore
size 5 µm, Thermo Electron Corporation). The mobile phase consisted of 0.1 %
TFA in MeCN (phase A) and 0.1 % TFA in H2O (phase B). The linear gradient
program was as follows: 10 to 100 % A over 30 min at a flow rate of 1.0 mL/min;
10-20 μL of solution were usually injected. Peptide: Rt, 11.30 min; λmax 276 nm.
3.4.1.2. Fourier transform infrared spectroscopy (FTIR):
FTIR spectroscopy was performed on drug loaded and free nanoparticles
to examine the immobilization of CTOP on its surface. MNPs bound CTOP
isolated from binding reaction mixture were lyophilized to preserve the integrity of
drug in the dried and powered MNPs colloids. These powdered samples were
used

for

FTIR

analysis

in

the

IR

spectrophotometer

(Perkin

Elmer

SpectrumTM 100). Spectra measurement were performed using attenuated total
reflection (ATR) on a single bounce diamond/ZnSe ATR crystal. The spectra
were collected in the mid-infra red range of 4000-600 cm-1 (2.5-25µm).
3.4.1.3. Fluorescent tagging of CTOP for binding validation:
Alexa flour 610 succinimidyl ester (NHS ester) (Life Technologies) were
used for tagging of CTOP. NHS esters were mixed with equal amount of CTOP
or PBS and were incubated overnight at room temperature. MNPs were added in
the mixture and rotate in tube rotator at room temperature.
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The collected

magnetic particle is used for quantification of attached peptide. Fluorescent
intensity was measured at wavelength 485/20nm-528/20 nm (Ex/Em) by
microplate

reader

(Synergy

HT,

Multi-mode

microplate

reader,

BioTek

Instrument, Inc., Winooski, Vermont, USA). MNPs added in mixture of NHS
esters and PBS does not show any fluorescent.

3.4.2. BDNF binding with magnetic nanoparticles:
For the binding experiment, different ratios of magnetic nanoparticles and
BDNF (1:0.05, 1:0.01, 1:0.015, 1:0.02, 1:0.025, 1:0.03, and 1:0.35) were mixed in
TE buffer pH 7.4, followed by incubating the mixture on a shaker (100 rpm) for 3
hrs at room temperature. After incubation, the magnetic particles bound with
BDNF were attracted by application of an external magnetic field. The
supernatant containing the unbound BDNF was collected and the pellet was
resuspended in appropriate volume of TE buffer pH 7.5 and stored at 2°C to 8°C
until further use.
3.4.2.1. BDNF enzyme linked immunosorbent assay (ELISA):
The binding efficiency (µg BDNF /mg of magnetic nanoparticles) was
determined by measuring the amount of BDNF in the unbound fraction by ELISA
(BDNF Kit from R&D Systems, Minneapolis, MN, USA) as per manufacturer’s
recommendation. 100 µl of assay diluent were added to each well of microplate
and were mixed with 50 µl standard, control, or sample. Plates were covered with
a plate sealer and incubated at room temperature for 2 hours. 100 µl conjugate
were added to each well following incubation and further incubated at room
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temperature for 1 hour. Each well was aspirated and washed with washing
solution, supplied with 200 µl substrate solution and incubated in dark at room
temperature for 30 minutes.

50 µl stop solution is added to each well and

fluorescent intensity is read at 450 nm by microplate reader (Synergy HT, Multimode microplate reader, BioTek Instrument, Inc., Winooski, Vermont, USA). The
amount of BDNF bound to the magnetic nanoparticles was calculated from the
difference between the total BDNF added and unbound BDNF measured in the
supernatant.
3.4.2.2. Fluorescent tagging of BDNF for binding validation:
Alexa flour 610 succinimidyl ester (NHS ester) (Life Technologies) were
used for tagging of CTOP. NHS esters were mixed with equal amount of BDNF
or PBS and were incubated overnight at room temperature. MNPs were added in
the mixture and rotate in tube rotator at room temperature.

The collected

magnetic particle is used for quantification of attached peptide. Fluorescent
intensity was measured at wavelength 485/20nm-528/20 nm (Ex/Em) by
microplate

reader

(Synergy

HT,

Multi-mode

microplate

reader,

BioTek

Instrument, Inc., Winooski, Vermont, USA). MNPs added in mixture of NHS
esters and PBS does not show any fluorescent.

3.5. Cell Culture
3.5.1. Preparation of Peripheral blood mononuclear cells (PBMC)
Normal peripheral blood mononuclear cells were isolated by density
gradient centrifugation process as described by Gandhi et al (2009). The
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Buffycoat leukopack, procured from the community blood bank, was diluted by
adding five volumes of phosphate-buffered saline (PBS) and overlaid over
histopaque (Sigma Aldrich, St. Louis, MO). The samples were centrifuged at
1200 × g for 20 min at room temperature. PBMCs were carefully retrieved from
the interface and washed twice with PBS. Red blood cells in the samples were
lysed using Ammonium-Chloride-Potassium Lysing Buffer (Life Technologies).
Collected cell pellet were resuspended in Roswell Park Memorial Institute
Medium (RPMI) -1640.
3.5.2. Peripheral blood mononuclear cells (PBMC) culture:
PBMCs isolated by density gradient centrifugation were cultured in RPMI
1640. RPMI 1640 culture medium was supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin (Gibco-BRL,
Gaithersburg, MD). Cells were cultured at 37OC in 5%CO2 incubator.
3.5.3. SK-N-MC cell culture:
SK-N-MCs, a neuroepithelioma cell line derived from a metastatic supraorbital human brain tumor, were cultured in minimum essential medium (MEM).
MEM was supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin,
and 100 mg/ml streptomycin (Gibco-BRL, Gaithersburg, MD). Cells were
incubated at 37OC in 5%CO2 incubator.
3.5.4. Primary human astrocytes (HA) culture:
Human astrocytes were cultured in astrocyte medium (AM) (ScienCell).
AM were supplemented with 2% FBS and 1% each of astrocyte growth
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supplement and penicillin/streptomycin solution (ScienCell). Culture was
performed in 37OC incubator with an atmosphere of 5% CO2 and 95% air.
3.5.5. Human brain endothelial cell (HMBVEC) culture:
Human brain endothelial cells (HMBVEC) were brought from ScienCell
Research Laboratories (Carlsbad, CA, USA) and cultured in endothelial cell
medium (ECM) (ScienCell). ECM were supplemented with 5% FBS and 1% each
of endothelial cell growth supplement and penicillin/streptomycin solution
(ScienCell). Culture was performed in 37OC incubator with an atmosphere of 5%
CO2 and 95% air.

3.6. Efficiency of MNPs bound CTOP:
3.6.1. Apoptosis inhibition efficiency:
1x106 PBMCs were treated either with 1.5 µm free or MNPs bound CTOP
for 4-6 hrs before treatment of morphine (1 µm). A schematic of different
treatment groups are depicted in figure 5. Following 60 hrs of morphine
treatment, cells were washed twice with cold PBS and resuspended in 1x binding
buffer at a concentration of 1 x 106 cells/ml. 100 μl of this resuspended cells were
aliquoted into a 5 ml FACS tubes, mixed with 5 μl each of Annexin V and 7-AAD
(BD Biosciences) and incubated at RT for 15 minutes in the dark. After
incubation, 400 μl of 1X binding buffer is added to each tube, mixed gently, and
analyzed within 1 hr by flowcytometry (FACScalibur). The untreated cells, which
served as control, are used for defining the basal level of apoptotic and dead
cells. The percentage of cells that have been induced to undergo apoptosis is
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then determined by subtracting the percentage of apoptotic cells in the untreated
population from percentage of apoptotic cells in the treated population. Cells
treated with camptothecin for 5hrs at 370C is used as positive control.

Figure 5: Schematic of the experimental design applied for apoptosis inhibition assay with MNPsCTOP nanoformulations.

3.6.2. Characterization of neuro-spinal architecture:
3.6.2.1. SK-N-MC staining:
Membrane staining of neuronal cells and measurement of spine
density was performed according to the method adopted from Smith et al (2009).
0.5x106 SK-N-MC cells were seeded onto 22x50mm glass coverslips placed in a
petri-dish. Following 24 hr of culture, cells were treated either with 1.5 µm free or
MNPs bound CTOP for 4-6 hrs before treatment of morphine (1 µm). Media from
the treatment was replaced every alternated day of culture and accordingly fresh
or MNPs-bound CTOP were added to each treatment. Different groups for this
treatment were similar to that shown in figure 5. Cells after 7th days of treatment
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were washed with PBS and fixed in 4% paraformaldehyde for 30 min at room
temperature. The fluorescent membrane tracer 1, 1’-Dioctadecyl-3,3,3’,3’tetramethylindocarbocyanine perchlorate (DIL; 5µg/ml in PBS) was directly
added onto the fixed cells and allowed to incubate at room temperature for 60-90
min. Further, coverslips are placed in small petri dishes containing PBS and
incubated at 4˚C for 12hr before preparation for confocal microscopy.
3.6.2.2. HIV co-infection of SK-N-MC with morphine treatments:
0.5x106 SK-N-MC cells were seeded onto 22x50mm glass coverslips
placed in a 90 mm petri-dish and allowed to adhere overnight. Cells were treated
with polybrene (10µg/ml) and 8hrs following this treatment 100 ng clade B HIV-1
was added to each treatment. 12 hr post-infection, non-absorbed virus was
washed with PBS, and HIV infection was carried for 7 days. Infected cells were
treated with Morphine and CTOP as explained above. Similarly, co-infected cells
were DIL stained and prepared for confocal microscopy. A schematic of different
co-infections groups are depicted in figure 6.

Figure 6: Schematic of the experimental design applied for efficiency determination of MNPsCTOP nanoformulations on morphine and HIV co-infection induced neuropathogenesis.
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3.6.2.3. Confocal Microscopy:
DIL stained SKNMC were mounted on the ProLong Gold antifade
reagents (life technologies) and dried away from light at room temperature. Leica
confocal laser scanning microscope was used for the morphological imaging of
these cells. Images were obtained using 60x oil immersion objectives at 488nm
(100%) illusion of an argon-ion laser. High numeric aperture and 2.5x electronic
zoom were maintained to visualize the individual cells and their spines. Three
dimensional images of individual cells were obtained using optical serial sections
at the rate of 0.14µm/section of the cells. Obtained images were used for
quantification of spinal density through ImageJ software program. Randomly
chosen dendritic segments of at least 10 cells from each treatment were
measured from the apical to basal regions away from the cell soma and spine
numbers were counted within this defined length. As shown in figure 7, spine
density is calculated as the number of spines per unit dendritic length and
expressed as spines/µm.

Figure 7: Schematic of a typical
dendrite segment: Spine density
from is measured by calculating
total number of spines in dendrite
segment divided by the dendrite
length (Venkata et al., 2013).
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3.6.2.4. Validation of HIV infection:
The culture supernatant from HIV infected SK-N-MC cells were collected
for quantitation of HIV p24 antigen using a p24 ELISA kit (ZeptoMetrix, Buffalo,
NY). Supernatant from each treatment groups were thoroughly mixed with lysing
buffer in 1:9 ratios. 200 µl of lysed samples were added in triplicate in different
wells of microplate. These wells are coated with anti-p24 monoclonal antibodies
which allow binding of p24 from lysed samples at 37oC overnight incubation.
Now, samples from each well was aspirated and washed 5-6 times with the wash
buffer. 100 µl of HIV-1 p24 detector antibody (biotin conjugated) was added to
each well and incubated at 37oC for 1 hour. Again wells were washed 5-6 times,
supplied with 100 µl of streptavidin-peroxidase working solution, and incubated at
37oC for 30 minutes. Solution from wells were aspirated, washed, and 100 µl of
substrate working solution is added into each well and incubated at room
temperature. Upon change of color to blue, 100 µl stop solution was added to
each well which cause change of color into yellow.

The optical density of

microplate at 450 nm gives the quantity of HIV p24 in each well.

Different

concentration of standard p24 antigen is also used simultaneously to plot
standard curve for quantitation.

3.6.3. Cell viability assay:
The MTT (Thiazolyl blue tetrazolium bromide) cell proliferation assay was
performed as described by Wilson et al (1990) with modifications. 1x106 PBMCs
were treated either with 1.5 µm free or MNPs bound CTOP for 4-6 hrs before
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treatment of morphine (1 µm). A schematic of different treatment groups are
depicted in figure 8. Following 48 hrs of morphine treatment, cells were treated
with 0.5% MTT at the rate of 100 µl per well and gently rocked in dark at room
temperature for 2-3 hrs. One volume STOP solution containing 20% SDS in 50%
dimethyl formamide were added to the rocking cell suspension in MTT solution
and further rocked gently in dark at room temperature for 1-2 hrs.

Cell

suspension is centrifuged at 2000 rpm for 10 minutes and supernatant were
collected for the spectrophotometric measurement of optical density of the
solubilized formazan at 550 nm. The optical density of formazan in each
treatment groups is directly proportional to the cell viability.
Cell viability for SK-N-MC were determined similar to that for PBMCs
except overnight culture media were changed with 1 ml fresh media before
addition of 0.5 % MTT.

Figure 8: Schematic of the experimental design applied for cell-viability assay with MNPs-CTOP
nanoformulations.

3.7. Efficiency of MNPs bound BDNF:
3.7.1. Apoptosis inhibition efficiency:
To see the protective effect of BDNF on morphine induced apoptosis,
1x106 PBMCs were treated with free and MNPs bound BDNF 12 hr before
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morphine treatment. Different doses of BDNF used were 10, 50, and 100ng/ml.
The concentration showing optimum efficacy was used for efficiency-verification
of MNPs-BDNF nanoformulations. Morphine was treated with a concentration of
10-7 M for 48 hrs and cells were processed for flowcytometry (FACScalibur)
based

apoptosis

measurement

as

described for the CTOP efficiency

measurement. A schematic of different treatment groups are depicted in figure 9
and 10.

Figure 9: Schematic of the experimental design applied for determination of optimum BDNF
concentration required for inhibition of morphine-induced apoptosis in PBMCs.

Figure 10: Schematic of the experimental design applied for apoptosis inhibition assay with
MNPs-CTOP nanoformulations.
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3.7.2. Quantification of cAMP response element-binding protein (CREB):
3.7.2.1. RNA isolation:
To see the BDNF-mediated effect on the expression of cAMP response
element-binding protein (cAMP), astrocytes were treated with free and MNPs
bound BDNF in the presence and absence of Morphine. Different treatment
groups for this experiment were similar that depicted in figure 10. Total RNA from
each treatment groups was isolated using RNAeasy kit (Qiagen) as per the
manufacturer’s protocol. 5-10 x106 cells were vortex-lysed using RLT buffer
supplied with the kit. Lysate were loaded onto the QIAshredder spin columns and
filtered by centrifugation at 10,000 rpm for 30 seconds. Filtered flow through were
mixed thoroughly with 350µl 70% ethyl alcohol and filtered in RNeasy silica
membrane column (RNeasy spin column) by centrifugation at 10,000 rpm for 30
seconds. Bound RNA in the column is washed once with 700 µl RW1 buffer and
twice with 500 µl RPE buffer, each at 10,000 rpm for 30 sec. Finally, RNA is
washed with 50 µl water for elution and stored at -80oC for future use.
3.7.2.2. Synthesis of cDNA:
Isolated total RNA was used for the synthesis of cDNA using high capacity
cDNA reverse transcription kits (Applied Biosystems). As per the manufacturer’s
protocol, 2x cDNA master mixes were prepared by mixing 10x reverse
transcription buffer, 25x dNTP mix, 10x random primers, RNAse inhibitors, and
reverse transcriptase enzyme. Total volume was adjusted to 20 µl with DNAse
and RNAse free water. Ratio of each components of this master mix is presented
in table 1 a and b. This 2x cDNA master mix is adjusted to 1x by adding one
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volume of 4µg total RNA. The mixture of master mix and RNA was subjected for
the thermocycling reaction in 2720 thermocycler (Applied Biosystems). Initially
reaction was fixed at 25oC for 10 minutes which allows primer annealing to the
RNA. The reverse transcription reaction was extended at 37oC for 120 minutes
and finally reaction is heated at 85oC for 5 minutes to inactivate the enzyme. The
cDNA yield is stored at 4 or 20oC for further use.

Table 1: (A) Ratios of ingredients for preparation of 2x cDNA master mix. (B) Ratios of 2x cDNA
master mix and mRNA for PCR reaction during cDNA synthesis.

3.7.2.3. Quantitative polymerase chain reaction (qPCR):
Relative abundance of CREB mRNA was assessed using the SYBR green
master mix from Stratagene (La Jolla, CA, USA). CREB specific primer was
brought from life technologies. Ratio of each components of this reaction mix is
presented in table 2.The real-time quantitative PCR was performed using the
Stratagene 3000 instrument that detects and auto-plots the difference in
fluorescence versus PCR cycle number and produces a continuous measure of
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PCR amplification. Time taken by amplification plot of each sample to reach a
fluorescence threshold above background gives their threshold cycle number
(CT) which is used to calculate relative gene expression in terms of transaccumulation index.

The quantity of RNA input is controlled by measuring

endogenous reference gene, β-actin. Additionally, data of RNA from treated
groups were normalized to that from control untreated groups.
2 X Master mix

12.5

µl

Reference dye

0.375 µl

20 X Primer/Probe

1.25

Water

8.375 µl

cDNA

2.5

µl

Total:

25.0

µl

µl

Table 2: Ratio of ingredients for qPCR reactions

3.7.2.4. Calculation of transcript accumulation index (TAI) or relative
expression
The ΔCT and ΔΔCT values were calculated for quantitation of TAI (Shively
et al., 2003). The ΔCT values was calculated by taking mean CT values of CREB
mRNA and subtracting the mean CT values of reference mRNA i.e. β-actin from
the same reverse transcription reaction.
ΔCT=CT (CREB) − CT (β−actin)
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The ΔΔCT values were calculated by subtracting the ΔCT of the untreated control
sample from that of treatment groups from the same reverse transcription
reaction.
ΔΔCT=ΔCT (treatment groups) − ΔCT (untreated control)
The transcript accumulation index (TAI) which is the relative gene expression is
given by,
TAI=2−ΔΔCT
Thus, this TAI measurement of gene expression is relative to the reference gene
and normalized to the untreated group. Importantly, PCR reactions are believed
to be 100% efficient. Only values with >95% efficiencies in each reverse
transcription reaction ascertain minimization of the calculations error.

3.7.3. Characterization of neuro-spinal architecture: SK-N-MC staining and
confocal microscopy:
Membrane staining of neuronal cells, confocal microscopy, and
measurement of spine density was performed similar to that described previously
for CTOP mediated effect. Different treatment groups for this experiment were
similar that depicted in figure 10. In brief, 0.5x106 SK-N-MC cells were seeded
onto 22x50mm glass coverslips placed in a petri-dish. Following 24 hr of culture,
cells were treated either with free or MNPs bound BDNF 12 hrs before morphine
treatment and cultured were maintained for 7 days. Media from the treatment
was replaced every alternated day of culture and accordingly fresh or MNPs-
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bound BDNF were added to respective treatment. Cells grown on cover slip were
fixed, stained, mounted, and analyzed under confocal microscopy.

3.7.4. Cell viability assay
Live/Dead amine-reactive dye (ViViD; Invitrogen) was used to determine
the viability of PBMCs (Pilakka-Kanthikeel et al., 2013). The cells were treated
either with free or MNPs bound BDNF 12 hrs before treatment of morphine. A
schematic of different treatment groups are depicted in figure 11. Following 48-60
hrs of this treatment, PBMCs were washed with 1X FACS buffer. Pellets were
mixed with dead cell discrimination dye supplied with the kit and incubated on ice
for 15 minutes in dark. The dead cell discrimination dye can only cross the cell
membranes of dead cells, where it reacts with cytoplasmic free amines. Finally,
cells were washed 2X with FACS buffer and analyzed within 1 hr by
flowcytometry (FACScalibur). The untreated cells, which served as control, are
used for defining the basal level of dead cells. The percentage of cells that have
been induced to undergo apoptosis is then determined by subtracting the
percentage of dead cells in the untreated population from percentage of dead
cells in the treated population.
Figure 11: Schematic of
the experimental design
applied for cell-viability
assay with MNPs-BDNF
nanoformulations.
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3.8. Formulation of liposomes-based magnetic nanocarriers:
3.8.1. Synthesis of ultrasmall magnetic nanoparticles:
The ultrasmall Fe3O4 MNPs were synthesized according to the coprecipitation method proposed by Sun et al (2004), with minor modification. All
glassware was cleaned overnight by aqua regia before used for reactions.
Briefly, Solution of 3 ml FeCl3 (0.487 g dissolved in 2 mol/L HCl) and 10.33 ml
H2O was stir-mixed with 2 mL Na2SO3 (0.126 g in 2 mL of water) drop-by-drop
within a minute.

Upon change of color from yellow to red-light yellow, this

solution was mixed into 80 mL NH3.H2O (0.85 mol/L) under vigorous stirring. A
black precipitate is quickly formed, which was allowed to crystallize further for
approximately 30 minutes under continuous stirring. The suspension was
washed and formation of stable MNPs was achieved by adjusting the pH from
7.5 to 3.0 and temperature from 90oC for first five minutes to 100oC degree for
about one hour. A change in color of dispersion from black to reddish-brown
suggests towards compact MNPs which is washed with water for at least three
times.

3.8.2.

Formulation

of

PEGylated

magneto-liposome

and

transferrin

conjugation
Preparation of PEGylated liposomes and encapsulation of MNPs in its
core was achieved simultaneously according to the extrusion method (Deng et
al., 2012). 7:2:0.5 molar ratios of EPC, Cholesterol, and mPEG2000-DSPE was
thoroughly mixed and evaporated under lower pressure. 1 mg ultrasmall MNPs
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was added onto the resultant thin lipid film for rehydration. PEGylated liposomal
vesicles containing MNPs is formed which is extruded by handheld extruder
(Avanti Polar Lipids, Inc.) containing polycarbonate membrane filter of different
pore size (400nm/200nm/100nm). Prior to extrusions, the extruder was warmed
on a hot plate at a temperature above the transition temperature of lipid. The
resulting unilamellar magnetized-liposomal nanovehicles of homogenous sizes
were separated from unloaded MNPs by centrifugation at 1,000 rpm x 2 minutes.
The purified magneto-liposomes were stored at 4oC further use. Fluorescent
labeling was achieved by adding 0.8% of CFPE relative to the total lipids into the
initial liposome formulation mixture.
Transferrin conjugation was achieved by mixing 0.5mg fresh transferrin
into 200µL of prepared magnetic-liposome at 37oC for ~30 min [36].
3.8.2.1. Validation of Transferrin conjugation:
Conjugation of transferrin in the periphery of magneto-liposomes was
determined spectrophotometrically with UV-visible spectrophotometer (Varian,
USA). Presence of transferrin-specific absorbance was measured by scanning
wavelength range from 250-400nm.

3.8.3. Determination of encapsulation efficiency (EE)
The encapsulation efficiency value designates the percentage of MNPs
loaded in liposomes and is given by the ratio between the iron concentration in
magneto-liposomes and that feeded into the encapsulation-mixture in the
beginning of formulation process. It is calculated as:
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EE (%) = (Iron concentration in magneto-liposome)/(Iron concentration
feeded in beginning of encapsulation process) x 100
3.8.3.1. Quantitation of encapsulated MNPs in liposome
Ammonium thiocyanate-based photometric assay was used to determine
the amount of encapsulated Fe3O4. Magneto-liposomal formulation was mixed
with Triton X-100 (1%, v/v) in a ratio of 1:1.5 causing de-encapsulation of MNPs.
One volume concentrated HCl (37%) was added to this mixture and incubated at
600C for 4 hrs. The suspension was centrifuged at 12,000 g for 10 minutes and
supernatant was collected for quantification of iron oxide. Equal ratio of
supernatant and 1% ammonium persulfate solution was mixed with one volume
0.1 M Ammonium thiocyanate and incubated at RT for 5 minutes. The absorption
of resulting red iron-thiocyanate was measured at 490 nm by a microplate reader
(Synergy HT, Multi-mode microplate reader, BioTek Instrument, Inc., Winooski,
Vermont, USA). A standard curve was prepared with known concentrations of
Fe3O4 in H2O.

3.8.4. Determination of colloidal- and fluorescent-integrity of magnetoliposomes:
The hydrodynamic size of freshly prepared magneto-liposomes was
determined by DLS (90 Plus Particles Size Analyzer, Brookhaven Instrument
Corp., USA). The nanocarriers were stored at 4oC and durability of their
structural-integrity was evaluated by measuring the size by DLS for up to 28
days. Further, their probable stability in peripheral-circulation was assessed by
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measuring the size at body temperature and in an in vitro closed circulatory
system. Magneto-liposomes were dispersed in the mixture of ECM and AM (1:1),
incubated at 370C for up to 28 hrs, and used for DLS measurement. To analyze
the sustainability of magneto-liposomal integrity in blood circulation, an in vitro
closed circulation system was set up using a bidirectional, self-priming peristaltic
pump (Mini Pump Peristaltic Pump Variable Flow C-2 Lab Pump, Fisher
Scientific). The nanoformulation was allowed to circulate in a 0.8 mm capillary for
120 times at a flow rate of 1ml/min. The circulating medium was prepared with
5% dextran-500 (Cat #: 50-247-495, Thermo Fisher Scientific, Boston, US) in
PBS which makes a viscosity equivalent to that of blood (4.5 centipoise).
Samples were collected after 10, 30, 60, and 120 circulations and subjected to
the size analysis by DLS.
The fluorescent-integrity of magneto-liposome was determined by
measuring the fluorescent intensity of associated CFPE at wavelength
485/20nm-528/20 nm (Ex/Em) by microplate reader (Synergy HT, Multi-mode
microplate reader, BioTek Instrument, Inc., Winooski, Vermont, USA).

3.9. In vitro blood-brain barrier (BBB) and nanocarrier transmigration:
3.9.1. Preparation of in vitro BBB model:
The primary human brain microvascular endothelial cells (HBMEC) and
human astrocyte (HA) cells were cultivated as per provider’s recommendations
The BBB model was established as described earlier by Gandhi et al. (2010).
The in vitro BBB model is developed in a bi-compartmental transwell culture plate
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(Product # 3415, corning life sciences, Mexico). The upper chamber of this plate
is separated from the lower one by a 10 µm thick polycarbonate membrane
possessing 3.0 µm pores. In a sterile 24-well cell culture plate with pore density
of 2x106 pores/cm2 and cell growth area of 0.33 cm2, 2 x 105 HBMEC and HA
were grown to confluency on the upper chamber and underside of lower chamber
respectively. Intactness of in BBB was determined by measuring the
transendothelial electrical resistance (TEER) using Millicell ERS microelectrodes
(Millipore). A mean TEER value of ~200 ohms/cm2 cell culture insert is
considered consistent with the formation of the BBB.

3.9.2. Transmigration of fluorescent magneto-liposomes across in vitro
BBB model:
Transmigration

study

of

magneto-liposomal

nanoformulations

was

conducted on the 5th-6th day of the BBB culture when ideal integrity of this
membrane was achieved as established by TEER measurement. Equal quantity
of transferrin conjugated and/or unconjugated fluorescent magnetic-liposomes
were added to the apical chamber and incubated at 370C in the presence or
absence of a magnetic force of 0.03-0.08 Tesla placed externally below the
trans-well’s basolateral chamber. Samples were collected from both the
chambers at different time points and Fluorescent intensity was measured at
wavelength 485/20nm-528/20 nm (Ex/Em) by microplate reader (Synergy HT,
Multi-mode microplate reader, BioTek Instrument, Inc., Winooski, Vermont,
USA).
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The relative apparent permeability coefficient was calculated from the
equation as:
Relative Papp = (Fluorescent intensity in basal chamber)/(Fluorescent
intensity in apical chamber) X 100
Where Papp: apparent permeability

3.9.3. Transmigration and efficiency of BDNF:
The in vitro BBB were established in bi-compartmental transwell culture
plate. Free and MNPs bound BDNF were added in upper well and a week
magnet was placed on the basal side of the plate. After 48 hr exposure of
magnetic force, samples were collected from the basal chamber and BDNF
transmigration ability was analyzed by BDNF ELISA as explained above.
The functional efficiency of transmigrated BDNF was determined by its
ability to induce CREB expression. Astrocytes were collected from the basal side
of in vitro BBB and used for total RNA extraction, cDNA synthesis and qPCR as
described above.

3.9.4. Cytotoxicity assay:
Cytotoxicity was assessed by MTS cell viability assay using CellTiter
96®Aqueous one solution cell proliferation assay kit (Catalog # G 3580,
Promega, USA). HBMEC and HA cells were seeded in 96-well tissue plates at a
density of 5 x 103 cells/well. After 24 hr, culture medium was replaced with 100 µl
fresh media containing different concentrations of Fe3O4 (from0.02-0.5 mgmL-1).
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20 µL of MTS solution was added into each well 24 and 48 hr post-treatment and
incubated at 370C for 2hr. Absorbance was recorded at 490 nm by microplate
reader (Synergy HT, Multi-mode microplate reader, BioTek Instrument, Inc.,
Winooski, Vermont, USA)
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4. Results and discussion:
The brain is one of the common target organs for HIV and recreational drugs.
Abusive drug is a risk factor for HIV-1 infection and AIDS progression (Nath et
al., 2002; Burdo et al., 2006; Hauser et al., 2007; Ferris et al., 2008; Rogers,
2011). Approximately 230 million are illicit drug users and it will increase by 25%
in next 3-4 decades (UNODCb, 2012). Opiates are among the most abused drugs.
About 26-36 million aged 15-64 have been estimated to use opioids in 2010
(UNODCb, 2012). It stimulates the μ opioid receptors that promote growth of HIV
and potentiate the HIV-related neurotoxicity (Nath et al., 2000, 2002; Hauser et
al., 2005). Despite significant advances in antiretroviral therapy, the worldwide
HIV morbidities, mortalities and associated NeuroAIDS continue. This is
attributed to the inability of the ARV drugs to completely eliminate HIV reservoirs
especially in the brain, which is mainly as a result of the impenetrability of most of
the ARV drugs across the BBB. Many of the new chemical entities, that do not
cross BBB under normal condition, aimed at treating brain disorders have failed
clinically because of their impenetrability across BBB. In recent years, the use of
magnetic nanoparticles has created significant interest in biomedicine and
biomedical engineering for applications including magnetic nanocarriers for drug
delivery systems and contrast enhancement agents in MRI for diagnostics. As
such, we investigated a novel magnetic nanoparticle based drug delivery system
for delivery of μ opioid receptor antagonist (CTOP, a μ opioid receptor blocker),
neuroprotective agent (BDNF), and ARV drugs across the BBB.
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4.1. Characterization of magnetic nanoparticles:
Size and morphology of MNPs were characterized by TEM. A typical TEM
micrograph of magnetic particles is shown in Figure 12. It shows that the average
size of magnetic particles is about 25-40 nm. It should be noted that the higher
surface to volume ratio enhances target-affinity of MNPs in comparison to the
micro-sized magnetic particles and can even manipulate and target at the
subcellular organelles levels.
(B)

(A)

Figure 12: (A) Transmission electron micrograph of Fe3O4 magnetic particles. (B) Size distribution
of magnetic nanoparticles: Average size of particles is 25-40 nm.

It has been established that smaller particles (<10 nm) are lost to
extravasation and larger particles (>200 nm) are quickly captured and excreted.
Particles between 10 - 70 nm have been shown to penetrate capillary vessels.
Thus, characterized MNPs can be compatible for enhanced drug delivery across
the tightly junctioned BMECs along the capillaries lining throughout the cerebral
microvasculature. Furthermore, In view of the fact that particles between 70 -200
nm possess longer blood circulation time, MNPs of 25-40nm size could be
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successfully hybridized with liposomes for synthesis of magnetoliposomes of
about 100 nm which will enhance the bioavailability of associated drugs.
Importantly, MNPs of about 30 nm size exhibit superparamagnetism and can
respond to an external magnetic field. Thus, it is possible to “remote control” the
movement of drug loaded nanoparticles for target-specific delivery by applying
the magnetic force at the exterior of desired site.

4.2. Effect of pH on surface charge distribution of MNPs:
Aqueous solutions of MNPs such as Fe3O4 perform amphoterism because
of adsorption of amphoteric hydroxyl (-OH) group and develop positive or
negative charges at the magnetite-water interface in pH-dependent manner
(Tombacz et al., 2006). The flexibility in the surface charge allow binding of wide
range of molecules either via direct, but week, ionic interactions to the MNPs
(Saiyed et al., 2009) or via surface coating or tethering agents (Yoo et al., 2012;
Wiogo et al., 2012). Thus, adsorption efficiency of a molecule on surface of
MNPs may be influenced by pH of reaction mixture. The magnitude of charge at
the surface of colloidal system is quantified by zeta potential using the zeta
analyzer. The measure zeta potentials at the surface of MNPs in different pH
range of Tris-EDTA buffer are shown in figure 13A. Similar to previous reports,
our results show that the isoelectric point (pI) of MNP is about 7.0 and have
positive and negative charge below and above pI. We get a significant negative
zeta potential value (-20.93) at pH 7.4, which is also the physiological pH range.
Thus, it is possible that at pH 7.4 MNPs may have sufficient charge for the
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adsorption of drug molecules. A model for electrostatic interaction between
MNPs and different drugs has been illustrated in figure 13B. Different drugs
possess reactive free functional groups such as OH, NH2, etc. These functional
groups may gain charges such as OH2+ and NH3+due to change in pH of
aqueous media and may influence peptide amphiphilic properties. Therefore,
negative charge on the surface of MNPs at pH 7.4 and possible positive charges
moieties in the drugs may allow direct binding via ionic interaction. The binding of
molecules to MNPs can be reversible due to pH variation, which may allow the
bound drugs to be released at the target site.
(A)

(B)

Figure 13: (A). Zeta potential (surface charge) of MNPs at different pH. (B). Schematic illustration
of proposed electrostatic interaction between MNPs and different drugs at pH 7.4.

4.3. CTOP adsorption on MNPs surface:
Infrared spectra obtained via Fourier transform infrared spectroscopy
(FTIR) can help in identifying the bonding present in an unknown molecule via
measuring the bending vibration of certain functional groups that are present in
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the sample (Balaji et la., 2009). In infrared spectroscopy, IR radiation is passed
through a sample. Some of the infrared radiation is absorbed by the sample and
some of it is passed through (transmitted). The resulting spectrum represents the
molecular absorption and transmission, creating a molecular fingerprint of the
sample. Like a fingerprint no two unique molecular structures produce the same
infrared spectrum.
(A)

(B)

Figure 14: FTIR spectra of transmittance: (A) % transmittance of MNP and “MNP+CTOP”. (B).
Difference between % transmittance of MNP and “MNP+CTOP”: transmittance of “MNP+CTOP”
obtained from FTIR were subtracted from transmittance of MNP only and difference in
transmittance at specific band ranges were co-related with presence or absence of functional
group associated with CTOP and aqueous medium.
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Fourier Transform Infrared Spectroscopy (FTIR) spectra were performed
to the lyophilized MNP bound with or without CTOP using a FTIR
spectrophotometer in wave range of 4000-400 cm-1 (Figure 14A). Typically,
bending vibration at about 900-1000 cm-1 corresponds to the O-H bond,
particularly for strong hydrogen bridges. Similarly, about 1000-1600 cm-1 is
typical of the H-O-H molecule (Lopez et al., 2010). In order to define the
presence of CTOP on MNPs, transmittance spectra of “MNPs-CTOP” were
subtracted from that of MNPs only and percent transmittance difference were
plotted (Figure 14B). Maximum variation in transmittance was detected at about
600-1600 cm-1. We can see a reduction in transmittance up to 18% at 1025 cm-1
for CTOP bound MNPs. Thus, change transmittance for “MNP+CTOP” in
compare to MNPs at these bands may correspond to two interrelated
phenomenon. First, hydroxyl groups from water molecule may have attached by
the hydrogen bonds in the iron oxide surface influencing the negative charge
distribution on surface which is reflected as higher negative zeta potential.
Similarly, water molecules (H-O-H) may have chemically adsorbed to the
magnetic particle surfaces, again influencing the surface charge. Second and
more importantly, presence of charge due to O-H or H-O-H on the surface of
MNPs might have allowed binding of CTOP resulting in change of bending
vibration of bonds which may be reason of reduced transmittance. Additionally,
we noticed that transmittance of “MNP+CTOP” is also reduced up to 7% at about
2870cm-1 and 3370 cm-1 which may reflect increased absorption at these bands
due to presence of additional CH and NH2 group of CTOP. Typically, frequency
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range for N-H group is 3300-3500cm-1 and that of C-H is 2700-3300cm-1. CTOP
absorption on the surface of MNPs was further verified using fluorescent-based
detection method. The Alexa flour 610 succinimidyl (NHS) esters were used for
tagging of this peptide. The NHS ester mediated bonding is most efficient and
convenient way to attach fluorophores to amine‑containing (R‑NH2) molecules
such as peptides, proteins, or amine‑modified nucleic acids. The stability of
amide bonds formed in the reaction is as good as that of peptide bonds. Thus,
selective linking of fluorophores to peptides opens window for many purposes
such as quantification, imaging, etc. As shown in figure 15, significant fluorescent
intensity were detected on the MNPs which were immobilized with dye tagged
peptide. Simultaneously, dye-exposed or non-exposed MNPs showed no trace of
fluorescent activity. This suggests that CTOP could successfully be immobilized
on the surface of MNPs.

Figure
CTOP

15:

Fluorescent-based

binding

verification:

Immobilization of red fluorescent
dye tagged CTOP on MNPs
emits fluorescence while MNPs
without

CTOP

fluorescence.
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4.4. Time kinetics and binding isotherm of CTOP to MNPs:
Data presented in the figure16A and 16B, shows the time kinetics and
percent direct binding of CTOP to MNPs. We found a significant binding of CTOP
to magnetic nanoparticles. The MNPs were dispersed in Tris-EDTA buffer (pH
7.4) and mixed with CTOP. The mixture was incubated in tube rotator at room
temperature and supernatant were collected at different time points from 5-240
minutes (Figure 16A). The unbound fraction of CTOP present in supernatant was
quantified by HPLC. The difference between the total CTOP added and unbound
CTOP was used to calculate the amount of CTOP bound to the MNPs. Maximum
binding was achieved at about 5 minutes of incubation which remained
unaffected till 4 hour of experimental duration. After the time kinetics of binding
was optimized, the CTOP binding efficiency was estimated by using different
ratios (Weight/Concentration),1:0.16, 1:0.33, 1:0.66, 1:1, and 1:1.33 of MNPs
and CTOP, respectively. Data presented in Figure 16B show the adsorption
isotherm of CTOP on MNPs. The result obtained from three independent
experiments indicates a maximum binding efficiency of about 140 µg CTOP per
mg of MNPs. It should be noted that time kinetics and loading efficiency
significantly affect the drugs sustainability and safe dosing. This eventually
influences drugs bioavailability. The sustainable binding of CTOP on MNPs for
over four hours is in accordance to our hypothesis where, under the non-invasive
magnetic influence, drug delivery to the target could be maximized before it
leaches out of the nanocarrier.
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(A)

(B)

Figure 16: (A). Time kinetics of CTOP binding onto MNPs. (B). Binding isotherm for CTOP on
MNPs.

4.5.

Functional efficiency of MNPs bound CTOP:

4.5.1. Inhibition of morphine-induced peripheral pathogenesis:
Exposure of morphine has been shown to modulate functions of various
immune cells such as phagocytes, T cells, dendritic cells, etc. (Eisenstein and
Hilburger, 1998; Messmer et al., 2006; Rivera-Amill et al., 2010; Saurer et al.,
2006; Wang et al., 2008). It significantly alters the expression of cytokines,
chemokines, etc. and induces apoptosis in both peripheral and neuronal cells.
Studies from our lab (Nair et al., 1988) have shown that morphine exposure
causes significant induction of apoptosis in PBMCs. Though different kinds of
opioid receptors exist, morphine exerts its effect through the μ opioid receptor.
Therefore, use of a μ opioid receptor antagonist could prevent the morphineinduced effect and may provide significant therapeutic benefits. We used D-PenCys-Tyr-DTrp-Orn-Thr-Pen-Thr-NH2 (CTOP), which is a highly selective and

82

potent μ receptor antagonist and remains impenetrable through the Blood Brain
Barrier (BBB). To compare the efficiency of MNPs bound CTOP with that of free
CTOP, PBMCs were treated with morphine and its effect on apoptosis induction
was analyzed using flow-cytometry (Figure 17). Annexin-V is the indicator
protein of the earliest events in apoptosis. As expected, more than 80% of
PBMCs were found to be Annexin-V positive when they were treated with
morphine (figure 17C and 17F). This effect was significantly reversed when cells
were treated with free or MNPs bound CTOP.

Figure 17: Flow-cytometry to evaluate the efficacy of MNPs bound CTOP on morphine induced
apoptosis in PBMCs: MNP bound CTOP (E) possess parallel efficacy to that of free CTOP (D) in
suppressing the apoptosis induced by morphine (C).
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Number of Annexin-V positive cells was reduced approximately by 50%
upon treatment with free CTOP and only 32% cells were found Annexin-V
positive. Similarly, MNPs-bound CTOP exerted equivalent apoptosis inhibition
efficiency and nearly 24% cells were found Annexin-V positive in this case.
Untreated or only MNPs treated cells showed near zero or insignificant induction
of apoptosis. Thus, our result suggests that efficacy of CTOP upon its binding to
MNPs is preserved.
4.5.2. Inhibition of morphine-induced neuronal pathogenesis:
Morphine crosses the BBB and believed to suppress CNS immune
responses by various mechanisms. It inhibits or downregulates various
inflammation-suppressing chemokines and cytokines such as macrophage
inflammatory protein, interleukin-8 etc (Mahajan et al., 2002). Also, morphine
have been shown to induce apoptosis in various CNS cells such as microglia,
astrocytes, neurons, etc. (Goswami et al., 1998; Yin et al., 1999; Hu et al., 2005).
All these immune-inhibitory effect of morphine could influence neuroinflammation leading to neuropathogenesis. In fact, deregulation of chemokine or
cytokine expression in CNS cells is a hallmark phenomenon associated with
neuronal degeneration. As such, morphine is putatively believed to acts
synergistically as a co-factor in neuropathogenesis. In particular, morphine has
been shown to synergize the HIV infection associated neurocognitive disorders
where spinal architecture of neuronal cells is significantly altered (Atluri et al.,
2013). Figure 18 shows altered spinal morphology of neuroblastoma cells upon
morphine treatment. This alteration of spinal architecture may negatively affect
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the synaptic plasticity during morphine exposure. Spine morphology play
important role in maximizing the effectiveness of the synaptic transmission
leading to cognitive modulation. Neuronal adaptation pattern is differentially
regulated during opioid addiction (Simonato, 1996) and cause rapid development
of tolerance, physical and psychological dependence. These opioid-dependence
associated disorders could significantly be diminished by supplementation of
anti-opioid agents which may prevent opioid-induced pathogenesis. However,
current treatments to alleviate the action of opioids are less effective at CNS
level, basically due to impermeability of therapeutic molecules across blood-brain
barrier. As a first step towards our hypothesis in developing MNPs-based
nanoformulations of anti-opioid agents, we analyzed the efficiency of MNPs
bound CTOP in preventing the morphine induced inhibition of spinal density as a
sign of neuronal degeneration (Figure 19).

Figure 18: Confocal microscopy to evaluate the efficacy of MNPs bound CTOP on morphine induced
neuropathogenesis: Free (E) and MNP bound CTOP (F) prevents the morphine induced spinal degradation
in neuroblastoma cells, SK-N-MC (B).
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Figure 19: Spinal density (No.
of spines/µm dendritic length)
of
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induced
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Free and MNP bound CTOP
on

prevention
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this

degradation.

As shown in figure19B, morphine treated cells showed a spinal density of
0.24±0.07 per µm2, whereas the same in untreated cells were approximately 1
per µm2 (P<0.0001). This significant decrease in morphine-induced spinal density
is prevented upon CTOP treatment. Both free and MNPs-bound CTOP showed
equivalent efficiency in checking the spinal degeneration (Figure 19; 18E and
18F). Cells with free CTOP and MNPs bound CTOP showed an average spine
density of 1.04±0.18 and 0.84±0.30 per µm2 respectively. These values were
comparable to that of untreated cells; however significantly higher than that of
morphine treated cells only (P<0.0001). Treatment of MNPs alone in cells
exposed or non-exposed to morphine (figure19; 18 C and 18B.) did not alter the
spinal density.

Thus, our result suggests that, similar to their efficacy in
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suppressing apoptosis induction in PBMCs, MNPs bound CTOP possesses
parallel effect to that of free CTOP in preserving the neuropathogenesis.
4.5.3. Inhibition of morphine-induced neuronal pathogenesis during HIV
infection:
As discussed previously, opioids act in synergy with HIV viral proteins and
cause greater immunosuppression. Regions of brain with higher opioid receptors
such as striatum and hippocampus have been shown to possess increased viral
titers (Nath et al., 2000; 2002; Hauser et al., 2005) which lead to faster
neuropathogenesis. As such, we analyzed the efficiency of MNPs-bound CTOP
in preventing the additive neuro-degeneration of morphine during HIV infection.
As reported previously from our laboratory (Atluri et al., 2013), HIV infections
lead to severe loss of spinal architecture in neuroblastoma cells (Figure 20B). In
compare with uninfected cells where spinal density was approximately 1 per µm2,
HIV infections reduce the spinal density to 0.35±0.17 per µm2 (P<0.0001) and,
though not significant, it goes further down to 0.30±072 per µm2 when exposed to
morphine during infection (figure20B, 20C; 21). To analyze the efficacy of our
MNP-CTOP nanoformulation in prevention of morphine-induced additive
neuropathogenesis, morphine exposed, HIV infected cells were treated with
MNPs bound CTOP. As shown in figure 20D and 21, this significantly prevented
the spinal degeneration. The spinal density significantly went up to 0.74±078 per
µm2 in compare to HIV infection (P<0.0002) or co-treatment of morphine with
infection (P<0.0001) (Figure 21).
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Figure 20: Confocal microscopy to evaluate the efficacy of MNPs bound CTOP on morphine and
HIV co-infection induced neuropathogenesis: MNP bound CTOP (D) prevents the spinal
degradation in HIV-infected, morphine co-treated neuroblastoma cells, SK-N-MC.
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Upregulation of μ opioid receptor and associated alteration in the
expression of pro- and antiapoptotic molecules, cytokines, and chemokines is a
common phenomenon during the HIV infection and opioid exposure (Peterson et
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al., 1994; Rojavin et al., 1993; Zhang et al., 2005; Beltran et al., 2006; El-Hage et
al., 2005). Apoptosis due to treatment with HIV-1 pathogenic protein gp120 and
morphine in μ-opioid receptors deficient mice gets lowered significantly in
compare with the wild types (Moorman et al., 2009). The magnetic
nanoformulations carrying μ-opioid receptor antagonist, CTOP, could possibly
block this receptor and, thus, in turn, may minimize the neuro-pathogenesis
exacerbated due morphine co-treatment and/or HIV infection. Therefore, as our
result suggests (Figure19-21), higher spinal density in HIV infected and morphine
co-treated neuronal cells, upon exposure of MNP bound CTOP, should be a
natural outcome than cells where no CTOP was supplied. This further, supports
our hypothesis in developing MNPs-based nanoformulations of anti-opioid agent.
4.5.4.

Cytotoxicity of MNPs-bound CTOP:

Figure

22:

Percent cell

viability of PBMCS and SKN-MC cells 48 hrs posttreatment with MNPs and
MNP-CTOP
nanoformulations.

Any exposure of external insults in the body, particularly when a sensitive
organ such as brain is targeted, must be validated for its cytotoxic effect. It has
been suggested that doses of MNPs within the permissible limit have nonsignificant safety concerns and are biodegradable (Jain et al., 2008). We
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examined the nonspecific cytotoxicity of MNPs with and without CTOP to PBMCs
and SK-N-MCs. Our results showed that MNPs was neither cytotoxic to PBMCs
nor to SK-N-MCs up to 48 hours of experimental treatments (Figure 22). The
unaffected percent cell viability due to treatments of MNP with or without CTOP
compared to untreated cells indicates their safe use as nanocarrier for drug
deliver.

4.6. BDNF adsorption on MNPs surface:

Figure
BDNF

23:

Fluorescent-based

binding

verification:

Immobilization of red fluorescent
dye tagged BDNF on MNPs
emits fluorescence while MNPs
without

BDNF

shows

no

fluorescence.

BDNF absorption on the surface of MNPs was determined using
fluorescent-based detection method. As explained for the CTOP tagging, the
Alexa flour 610 succinimidyl (NHS) esters were used for tagging of this protein.
Fluorescent tagging is mediated by amide boding between dye and
amine‑containing (R‑NH2) moiety on proteins.

This stable tagging provides

could be used for many purposes such as quantification, imaging, etc. Significant

90

fluorescent intensity was detected on the MNPs which were immobilized with dye
tagged BDNF (Figure 23). Simultaneously, dye-exposed or non-exposed MNPs
showed no trace of fluorescent activity. This suggests that BDNF could
successfully be immobilized on the surface of MNPs.
4.6.1. Time kinetics and binding

isotherm

of

BDNF

to

magnetic

nanoparticles:
Several in-vitro and in-vivo studies demonstrate magnetically guided drug
targeting (Alexiou et al., 2006; Lubbe et al., 1996). Here we characterize binding
isotherm and kinetics of BDNF on MNPs, which is essential for determination of
drugs sustainability on carrier and their safe dosing and bioavailability as well.
The nanoformulation of MNP carrying BDNF was prepared by using different
ratios of MNP and BDNF (1:0.05, 1:0.01, 1:0.015, 1:0.02, 1:0.025, 1:0.03, 1:0.35)
in TE buffer (pH 7.4).

Figure 24: Binding isotherm of
BDNF on MNPs: Ratios of 1:0.05,
1:0.01, 1:0.015, 1:0.02, 1:0.025,
1:0.03, and 1:0.35 of MNP and
BDNF were incubated for 3 hrs
binding.

Binding

efficiency

(µg

BDNF/mg MNP) was measured by
BDNF ELISA.

The BDNF ELISA was performed to calculate the binding efficiency (µg
BDNF /mg of magnetic nanoparticles) at different MNPs to BDNFs ratios. MNPs
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bound BDNF were separated from the binding reaction mixture using magnetic
force and unbound fraction of BDNF present in supernatant was quantified. The
difference between the total BDNF added and unbound BDNF was used to
calculate the binding isotherm of MNPs-BDNF binding. As shown in figure24, a
maximum binding efficiency of 177 µg of BDNF per mg of MNP is achieved in 3
hours of binding-reaction time. This corresponds to approximately 70%
immobilization efficiency of BDNF on MNPs, suggesting an efficient and effective
binding. Thus, similar to use of CTOP-magnetic nanoformulations, BDNFnanoformulations are also in accordance to our hypothesis and could be used for
targeted brain delivery under the non-invasive magnetic influence.

4.7. Apoptosis inhibition efficiency of MNPs bound BDNF in leukocytes:
The mechanism of programmed cell death in apoptosis is triggered by a
variety of internal and external stimuli. It could lead to sever pathological features
such as those defined in case of certain inflammatory diseases of the brain and
CNS infections (Kaul et al., 2001). Opioids are known to induce apoptosis in all
types of cells including lymphocytes and neuronal cells (Nair et al, 1997; Yin et
al., 1999; Singhal et al., 1998; goswami et al., 1998; Singhal et al., 1999; Freier
and Fuchs, 1993; Fuchs and Pruett, 1993), mainly through the caspase-3
activation. Thus, inhibitors of caspase-3 activity can rescue cells from the
apoptotic cycle (Xia et al., 2010). In particular, use of such factor in addition to μ
opioid receptor antagonist could be of therapeutic benefit in treatment of opiate
addiction. Neurotrophic factor, BDNF is a class of such apoptosis-inhibitors which
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acts by blocking caspase-3 activity. As such, apoptosis-inhibition efficacy of
MNP-BDNF nanoformulations was evaluated. Here again, morphine was used as
agent for the apoptosis induction in lymphocytes.

Figure 25: Flow-cytometry to evaluate the efficacy of MNPs bound BDNF on morphine induced
apoptosis in PBMCs: (A). % Annexin-v positive cells showing apoptosis-inhibition effect of
different concentration of BDNF upon morphine treatment. (B). % Annexin-v positive cells
showing apoptosis-inhibition effect of MNPs- BDNF nanoformulations upon morphine treatment.
(C). Representative histogram showing Annexin-v expression upon different treatments.
Camptothecin is an established apoptosis inducer and serves as positive control.

To check whether BDNF activity is retained after immobilization by direct
binding to MNP, we evaluated and compared the efficiency of MNPs bound
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BDNF to that with free BDNF (Figure 25). As expected, morphine treatment
significantly (10-7M) induced apoptosis in PBMCs (55%) in compare with
untreated cells (p=0.006) (Figure 25A). We found that pre-treatment of BDNF
could prevent the morphine-induced apoptosis in dose dependent manner. The
optimum response was achieved at 50ng/ml (p=0.019) and thus, same
concentration was used for our further experimentation. Our results confirmed
that morphine induces apoptosis in PBMC, and this effect was reversed by free
BDNF. Similarly, morphine-induced apoptosis was also reversed upon treatment
with MNP-BDNF nanoformulations (p=0.014; figure 25B and 25C). Cells were
also treated with camptothecin which serves as positive control for apoptosis
induction (figure 25C). This suggests that binding of MNP did not interfere with
the enzymatic activity of BDNF. These results showed that BDNF efficiently
bound to MNPs and that bound form is as effective as that of free unbound
BDNF in suppressing the apoptosis induced by morphine.

4.8. Efficacy of MNPs bound BDNF in Astrocytes:
4.8.1. Modulation of CREB expression in Astrocytes:
CREB play vital role in many neuronal-based responses such as memory
and amnesia (Bourtchuladze et al., 1994; Bernabeu et al., 1997; Taubenfeld et al.,
1999; Cammarota et al., 2000; Viola et al., 2000). Increased CREB phosphorylation

has been shown to involve in memory consolidation (Jie luo et al., 2013).CREB
mediated activities also functions as connecting bridge between opioid-induce
secondary messenger systems and consequent alterations in gene expression
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during opioid exposure. As such, decreased phosphorylation of CREB has been
noticed due to morphine-induced stimulation of opioid receptor (Mahajan et al.,
2005). In this context, BNDF could exert beneficial therapeutic molecules
because it assist in long-term memory formation, mainly via the activation of
CREB in a time-dependent manner (Kwon et al., 2011; Alonso et al., 2005).
Therefore, study was carried out to evaluate the ability of MNP-BDNF to
modulate the morphine induced CREB expression in human brain astrocytes.
(B)

(A)

Figure 26: Trans-accumulation index (TAI) showing CREB expression: (A). TAI showing effect of
Free BDNF and MNPs-BDNF nanoformulations on CREB expression. CREB expression is
significantly upregulated either upon free or MNPs bound CTOP treatments. (B). TAI showing
effect of Free BDNF and MNPs-BDNF nanoformulations on morphine mediated inhibition of
CREB expression.

As shown in figure 26A, treatments of BNDF significantly upregulates
CREB expression (TAI= 2.4±0.25, p=0.033).

Similarly, MNPs bound BDNF

resulted in a TAI value of TAI=2.43±0.27 (p=0.007). Thus, these comparable
CREB expressions support our hypothesis that, irrespective of nanoformulations
use for peripheral or neuronal cells, free and MNPs bound BDNF possess equal
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efficacy. Further, BDNF nanoformulations were tested for its ability to suppress
the morphine-induced effect in astrocytes. As expected, in consistent with
previous reports (Mahajan et al., 2005), morphine resulted in significant
downregulation of CREB (TAI=0.533±0.03; p=0.0004; Figure 26B). When
morphine exposed cells were pre-treated either with free or bound BDNF,
downregulation of CREB expression was significantly reversed. Free and MNPsbound MNPs resulted in TAI values of 1.25±0.03 (p=0.008) and 1.253±0.06
(p=0.03) respectively (Figure 26B). This further suggests that nanoformulation
could be used to alleviate morphine induced effects in CNS related problems.
4.8.2. Inhibition of neuronal pathogenesis:
Studies have shown that drug addiction alters the function of the neuronal
circuit which includes changes in neuronal plasticity and synaptic transmitter
release (Sarti et al., 2007; Frankfurt et al., 2011; Nestler, 2001). In the same line,
morphine administration produces a persistent decrease in dendrite length and
dendritic spine in neurons of different brain regions such as nucleus accumbens,
visual cortex, sensory cortex, etc (Li et al., 2007; Robinson and Kolb, 1999). Here
again, BDNF treatment has been reported to increase dendrite numbers
(Bramham and Messaoudi, 2005; Chapleau et al, 2008). Therefore, we tested
the ability of our nanoformulation to facilitate the neuroprotective efficacy in
maintaining the dendrite spine density. Here also, morphine treatment resulted in
decreased spine density(0.055±0.02 per µm2; p< 0.002) in compare to untreated
groups (Figure 27A and 27B). This significant decrease in morphine-induced
spinal density is prevented upon BDNF treatment. Both free and MNPs-bound
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BDNF showed equivalent efficiency in preventing the morphine induced spinal
degeneration (Figure 27B).
(A)

(B)

Figure 27: Efficacy of MNPs bound BDNF
on morphine induced neuropathogenesis:
Confocal microscopy showing effect of
free

and

MNP

bound

CTOP

on

prevention of morphine induced spinal
degradation in neuroblastoma cells, SKN-MC.

(B)
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showing

morphine

induced
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degeneration and effect of Free and MNP
bound BDNF on prevention of this
degradation.
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Pre-treatment of MNPs bound BDNF resulted in an average spine density of
0.258±0.09 per µm2 (p=0.007). Our result suggests that, similar to their efficacy
in suppressing morphine-induced apoptosis in PBMCs, BDNF nanoformulations
possesses comparable effect to that of free BDNF in preserving the
neuropathogenesis.

4.9. Cytotoxicity of MNPs-bound BDNF:

Figure

28:

Percent cell

viability of PBMCS 48 hrs
post-treatment with MNPs
and

MNP-BDNF

nanoformulations.

One of the major concerns while using nanomaterials in medicine is that of
potential toxicity. As such, evaluation of cell viability is important for the
nanoparticle application in medicine. We examined the nonspecific cytotoxicity of
MNPs with and without BDNF to PBMCs.

Our results showed that MNPs

possess insignificant toxicity for PBMCs. Approximately 95% cells were found
live (Figure 28), in both, MNPs and MNPs-BDNF treatments. This unaffected
percent cell viability suggests their safe use as nanocarrier for drug deliver. In the
same line, based upon in vivo studies, it has been suggested that doses of MNPs
within the permissible limit have non-significant safety concerns and are
biodegradable (Jain et al., 2008).
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4.10.

Characterization of MNPs-based liposomal nanocarriers:

Magnetite (Fe3O4) is the most commonly used magnetic nanoparticles in the
field of biomedicine, mainly due to its biocompatibility. In accord with the basics
of nanotechnology, MNPs of different sizes, ranging from a few up to tens of
nanometers, have been extensively investigated for disease diagnosis and
target-specific improved drug delivery. Generally drugs are either directly
immobilized on the MNPs surface or tethered via coating of organic/inorganic
surfactants such as PEG. In either case, attached drugs are exposed to external
environment and possess threat of rapid decomposition due to metabolic
(enzymztic mainly) activity of peripheral circulation (blood) before it could reach
to target. Thus, an approach to protect drugs from exterior must be devised for
advancement of MNPs-based drug delivery. Recently, a hybridization strategy
where MNPs is encapsulated in liposomes termed “Magneto-liposome (ML)”, has
emerged as a possible solution.

4.10.1. Characterization of ultrasmall magnetic nanoparticles:
Potential application of ML-based drug delivery across blood-brain barrier
(BBB), in CNS, is very limited. In the wake of CNS sophisticacy, an ideal drug
delivery carrier should co-incorporate maximum drug bioavailability with minimum
waste constituent. One way this could be achieved is by increasing the
encapsulation potential of liposomes with no affect on overall ML size. Higher
loading density of MNPs in liposomes would require synthesis of smallest
particles in the nanometer range

suitable for the targetting and drug-
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bioavailablity. Particles of >10 nm can sustain in the the systemic circulation;
however, that of lesser size lost due to permeability of vascular endothelium and
prohibits drugs to reach target-site.
There are several methods to synthesize Fe3O4 nanoparticles such as coprecipitation, microemulsion, high temperature decomposition, oxidation of
magnetite, etc. (Sun et al., 2004; Frascione et al., 2012; Jayapaul et al., 2011; ).
Co-precipitation is regarded as one of most efficient, circumstance friendly and
cost-effective way to prepare MNPs on nanoscale. This method mainly uses two
different approaches to reduce ferrous ion from FeCl3 - either by Na2SO3 or
FeSO4. The later approach results in formation of rod shaped nanoparticles of
over 30 nm. Liposomal encapsulation of particles of this shape and size will
have a greater impact on the overall size of MLs and may not be suitable for
delivery across many physiological barriers such as BBB, stomach epithelial, etc.
Most importantly, it may significantly downgrade the colloidal stability of MLs in
the peripheral circulation. The Na2SO3-based reduction approach possesses
advantage in producing round MNPs with smaller size, probably due to the gentle
reduction ability from Na2SO3 in aqueous medium. Maghemite (Fe2O3) is the
primary product of this reduction reaction which is further oxidized under acidic
condition resulting in Fe3O4 nanoparticles. As determined by TEM, ultrasmall
magnetite nanoparticles of 7-10 nm possessing excellent dispersion property in
aqueous medium could be synthesized by this approach (Figure. 29A). The
nano-sized particles possess remarkably higher specific surface area which
improves drug loading ability and dissolution rate influencing the bioavailability.
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These particles could also manipulate and target at the subcellular organelles
levels. The crystal structure of synthesized magnetite particles was confirmed by
X-ray diffraction spectroscopic measurement (Figure 29B). The X-ray spectrum
consists of magnetite-specific peaks which correspond to 220, 311, 400, 511,
and 440 planes.

Figure 29: Characterization of ultrasmall magnetite nanoparticles: a) TEM image showing MNPs
of 7-10 nm. b) XRD spectrum showing magnetite-specific characteristics plane.

Magnetic hysteresis loops for these particles, which displayed strong
magnetic property, were measured between +1200 to − 1200 Oersted (Oe). As
shown in figure 30A, the nanoparticles exhibit a superparamagnetic behavior with
no coercivity and remanence at room temperature. The superparamagnetism can
be utilized for simultaneous monitoring and quantitation of MNPs distribution
specific or nonspecific to various tissues. Thus, quantitation of localization of
MNPs associated drugs could be possible using techniques like magnetic
resonance imaging (MRI) and magnetometery due to variation in the surface
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charge of naked and drug-bound nanoparticles leading a way for determining the
site-specific optimal or suboptimal drug-dosing. Distribution of charge on the
surface of synthesized MNPs was determined by measuring the zeta-potential at
different pH level of dispersion solution (Figure 30b). Interestingly, with pH values
changing from acidic to basic, zeta potential of MNPs alternated from positive
charge of +26 mV at pH 4.75 to negative charge of -23 mV at pH 8.5.The
isoelectric point of MNPs was determined at ~7.1 pH. We noticed that content of
dispersion solution also affects the surface charge of MNPs. As such, in TrisEDTA buffer (pH 7.4), MNPs displayed zeta potential of approximately -21 mV
which is nearly equivalent to that obtained in H2O with pH 8.5 (-23 mV).

Figure 30: a) Magnetic hysteresis loop of MNPs showing no coercivity and remanence at
room temperature suggests its superparamagnetic behavior. b) Surface charge of MNPs
varies according to pH values of suspension solution.

Charge on the surface of Fe3O4 particles is developed due to its
amphoteric property in aqueous media. Acting as Lewis acid, at the hydrated
solid/water interface, magnetite adsorb/coordinate water or hydroxyl group and
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gets H+/OH- ions along it surface. These ions can be replaced by other organic
or organic anion, form hydrogen bond, and adsorbs proton or cations. This could
allow direct immobilization of various biomolecules/molecules on MNPs surface
via hydrogen bonding, hydrophobic interaction, and electrostatic repulsion (Peng
et al., 2004; Yu et al., 2013). Also, the surface charge of magnetic nanoparticles
could be converted either to positive or negative with different kinds of coating
such as, the polyelectrolyte coating, silica coating, etc. (Ding et al., 2007; Gittins
et al., 2001; Chen et al., 2008).

4.10.2. Characterization of ML nanocarriers:
As stated earlier, greatest challenge towards the successful application of
MNPs in drug delivery is protection of associated drugs from enzymztic
decomposition of blood circulation. Naked MNPs also interact with various
plasma/serum proteins which could significantly affect the potential outcome of
its applications in other drug-related and unrelated biological uses such as target
specificity, MR imaging, etc. Although liposomal encapsulation of MNPs is looked
upon as potential solution of these concerns, physiological integrity and stability
of magneto-liposomal colloids needed to be addressed for their effective
manipulation. Additionally, ways to maximize the target-reachability must be
incorporated in the nano-formulated carrier. It has been suggested that
modifications such as PEGlyation of liposomal surface could improve the
inherent poor stability of conventional liposomes. Also, liposomal surface can be
engineered for active targeting by applying surface charge modifications and/or
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conjugation of antibodies/ligands specific to cells or tissues. Here, we used
PEGylated lipid, DSPE-PEG, for liposome formulation. The PEG in this lipid is
tethered to the hydrophilic head of phospholipid bilayer; thus, upon liposomal
formulation PEG will be extended outside from the surface. In addition to provide
colloidal stability, PEGylation prevents liposome-induced immunogenicity and
could also reduce their uptake by reticuloendothelial system resulting in improved
plasma circulation time and increased bioavailability to reach the target (Suri et
al., 2007; Peng et al., 2012).
To maximize the reachability of nanocarrier to the target i.e. in this case
transportation across BBB, we embedded transferrin, a ligand for the HBMVECs
specific transferrin receptor, on the surface of PEGylated ML. Presence of MNPs
and BBB specific receptor’s ligand on the same carrier will synergize the
transmigration across BBB. While MNPs will influence the movement in the brain
under external magnetic force, presence of ligand will add to this effect by
providing uptake-specificity for BBB cells (in this case for HBMVECs). The ML
possessing such dual targeting mechanisms could be epitomized for many other
target-oriented deliveries. We further expanded the multifunctionality of ML by
making it fluorescent. This was achieved by adding green fluorescent tagged
phosphatidylethanolamine, namely CFPE, in the liposomal formulation mixture.
Fluorescent addition to ML could serve as a tool for nanocarrier associated
pharmacokinetics study such as quantification of cellular uptake or entrapment,
tracking localization in tissues, etc. More importantly, co-incorporation of
fluorescent in the MNPs-based nanocarrier provides two different imaging
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options, MNPs-based imaging such as MRI and magnetometery and fluorescentbased imaging. We believe that easy availability of fluorescent-based imaging
technique will widen the use of ML as convenience and cost-effective tools in the
targeted-drug delivery. Nonetheless, MNPs could always be available for
targeted delivery and more powerful imaging, such as MRI, could be applied as
per necessity.

Figure 31: Characterization of magnetic-liposomes (MLs): a) Dynamic laser scattering
(DLS) measurement of hydrodynamic size distribution of MLs. Average diameter size of
this nanoformulation was approximately 130 nm. b) TEM image of ML nanocarriers
containing MNPs (black dots) supports the size of MLs as determined by DLS
measurement.

Size of PEGylated magneto-liposomal nanocarriers formulated using
extrusion technique was determined by DLS (Figure 31A) and further TEM was
performed to verify this formulation (Figure 31B). As evident from both figures,
the average diameter size of this nanoformulation was approximately 130 nm.
Encapsulation of MNPs into the liposomes have been proved to be difficult task
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and a maximum of 15% EE have been shown earlier (Deng et al., 2012). We
here report EE of 60.0% which could possibly be attributed to the ultrasmall sized
MNPs. In the same line, TEM image shows that the ML formulation is filled with
ultrasmall MNPs. Nonetheless, EE of ultrasmall MNPs in liposome can be
manipulated by changing the ratio of particles with liposomes during the
formulation process. Higher MNPs content may significantly improve the contrast
enhancement effect of MRI. Larger sized MNPs have been previously used due
to their MR contrast enhancement effect (Qiao et al., 2012; Jun et al., 2005);
however, in view of transportability across BBB, smaller MNPs as small as 10 nm
may provide better pliantness to the liposomes which, in addition to their use as
MRI, could remarkably influence its transendothelial extravasation under external
non-invasive magnetic influence. More importantly, higher EE i.e. more no of
MNPs in a liposome will provide higher per unit loading surface area resulting in
significantly higher per unit drug loading efficiency of ML nanocarriers.
Furthermore, it is challenging to maintain the mono-dispersibility of the
nanocarriers. It becomes even more important in view of their potential
application in targeted drug delivery. Although PEGylation add to the colloidal
stability and assist in maintaining the liposomal mono-dispersion, incubation
temperature during the formulation process plays a vital role. We achieved highly
mono-dispersed liposomes using an incubation- and extrusion- temperature of
~40oC which is higher than the thermogravimetric analysis points for all lipids.
Homogenous size of ML nanocarriers was attained by using polycarbonate filter
membrane of different pore-size (400 nm/200 nm/ 100 nm) during the extrusion
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process. Notably, molar concentration ratio of DSPE-PEG used during the
formulation process was controlled within 10%, a critical micelles concentration
limit above which PEG influence the micelles formation. The formulated ML was
subjected to DLS for measurement of zeta potential which showed near neutral
charge of -0.8±0.2 mV on the surface of this nanocarrier. Thus, possibility of
charge-mediated cellular uptake of ML will be minimized in the peripheral
circulation i.e. external magnetic force will remain the only controlling force of this
nanocarrier for effective movement up to the target area. In order to provide more
established BBB specificity to this nanocarrier, transferrin was conjugated on its
surface. Transferrin is one of rare proteins which have free access across the
intact BBB and carry essential nutrients into the brain. Transferrin conjugation on
ML surface was confirmed by spectrophotometry (Figure 32).

Figure 32: Characterization of transferrin
conjugation to MLs: spectra of transferrin
conjugated MLs shows rise of the optical
density peak in the transferrin-specific
wavelength range.

Similar to the previous study of Xu et al (2008), spectra of transferrin
conjugated magnetic-liposomes showed rise of the optical density peak in the
transferrin-specific wavelength range. It should be noted that inclusion of less
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than 10% of PEG in formulation mixture results in homogenous PEGylation
rather than forming thick corona which was noticed in the work of Gao et al
(2006). The shielding effect of thick PEG corona may cause improper ligand bind
and also may prevent proper interaction of ligand to the receptor. In other hand,
the homogenous embedding of 2000 Da PEG on the ML surface may have
negligible or zero interference in the interaction of 80 kDa transferrin and its
cellular receptors. Similarly, homogenous transferrin distribution should not affect
the original objective of PEG in providing colloidal stability. As determined by
DLS, Transferrin conjugation to the ML surface neither has significant effect on
its hydrodynamic size nor did it affect the surface charge distribution.

4.10.3. Physiological sustainability of ML nanocarriers:
The formulated ML nanocarriers were assessed for its sustainability in the
physiological equivalent temperature and circulation. Nanocarriers suspended in
the PBS were incubated in 37oC for up to 30 hours and their size was measured
at different time points using the DLS. As shown is figure 33A, size of these
formulations remained unchanged. Similarly, fluorescent intensity emitted from
equal amount of ML carriers was constant through-out the incubation period
(Figure 33A). It should be noted that fluorescent integration in ML improves its
multifunctionality such as easy manageable quantification and visualization of
carriers during experimental settings. This was achieved by adding green
fluorescent tagged lipid, namely CFPE, in the liposomal formulation mixture.
Sustainability of these carriers was further evaluated in the in vitro closed
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circulation system which consists of a bidirectional, self-priming peristaltic
capillary pump. A schematic of this pump is shown in figure 33B. Here also, both,
the structural integrity and fluorescent intensity of ML nanocarriers remained
unaffected through 120 equivalent blood-circulations of experimental settings
(Figure 33D). Fluorescent intensity study together with the DLS measurement
shows that the formulated ML nanocarriers could sustain its structural integrity in
the simulated blood circulation and physiological temperature for considerable
amount of time. This suggests toward the possible use of fluorescent ML
nanocarriers for in vivo drug delivery and optical imaging. Nanocarriers were also
looked for their storage durability at 4oC for around one month. Again, constant
diameters were determined throughout the storage period (Figure 33C). Also, as
expected, hydrodynamic difference between the diameter of transferrin
conjugated or unconjugated liposomes remained less than 10 % throughout the
storage time. Nonetheless, it is worth mentioning that the colloidal stability and
optical properties of the ML nanocarriers remained unaffected due Transferrin
conjugation. This suggests that these ML nanocarriers possess longer storage
stability and drugs loaded on these carriers could have minimum leaching effect.
In fact, consistent florescent intensity either during exposure of physiological
temperature, peristaltic circulation or storage implies towards minimum leakage
from formulated ML nanocarriers. Larger size MNPs (35 nm) were also tested
for encapsulation in the liposomes. However, stability and precipitation remained
an issue because ML could sustain in suspension for not more than couple of
hours.
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Figure 33: Characterization of MLs sustainability: a) Florescent intensity (black) and
average diameter (Blue) of ML nanoformulations incubated at 37oC. It suggests that
structural integrity and fluorescent intensity of ML nanocarriers remained unaffected up
to 30 hrs of experimental period. b) Schematic of in vitro closed circulation system: The
bidirectional, self-priming peristaltic capillary pump simulates physiological equivalent
blood-circulation. c) Florescent intensity (black) and average diameter (Blue) of ML
nanoformulations after various round of in-vitro circulations. It suggests that structural
integrity and fluorescent intensity of ML nanocarriers remained unaffected up to 120
circulations of experimental period. d) Average diameter (Blue) of ML nanoformulations
in storage at 40C suggests its structural integrity up to 28 days of experimental duration.
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4.11.

Transmigration of ML nanocarriers across BBB:

The BBB transmigrability of the ML nanocarriers was evaluated using an
in vitro human BBB model. As described previously by Gandhi et al. (2010), the
BBB model was established in a bi-compartmentalized transwell where HBMECs
and HAs were grown to confluency on the upper chamber and underside of lower
chamber respectively. The intactness of grown BBB was determined by TEER
values. A TEER value of ~200 ohms/cm2 in compare to the control (non-cultured
wells) is considered consistent with the formation of intact BBB. Following the
TEER determination, fluorescent ML nanocarriers were subjected to different
wells either in presence or absence of external magnetic force. As shown in
Table 3, initial TTER values of all treatment groups were close to standard 200
ohms/cm2. As expected, significantly higher transmigration of ML nanocarriers
were detected across BBB due to exposure of external magnetic force (Figure
34A and 34B). Incorporation of fluorescent in the ML nanocarrier was used for
quantification of its transmigration from apical to basolateral layers in the BBB
model. Transferrin conjugated ML nanocarriers in presence of external magnetic
force (Force) showed higher transmigration than nanocarriers which lacks
external force (No force). Approximately 2-3 folds (100% vs 30-50%) increased
transmigration was achieved and this continued till 16 hrs of experimental period.
It could possible that magnetic force may allow transient change in BBB
permeability resulting in increased transendothelial extravasation of ML
nanocarriers. Magnetic force induced increased BBB permeability has been
reported earlier in few studies. Working with the Fe3O4-PEG nanocarriers, Qiao

111

et al (2012) showed an alteration in BBB permeability after 4 hrs of exposure.
Similarly, treatment of polysorbate derived nanoparticles resulted in sharp
increase in permeability from 4-7 hrs and accordingly TEER values were
reversed from less to high [Rempe et al., 2011].

Figure 34: a) Relative transmigration of ML nanocarriers in the presence and absence of
external magnetic force across in vitro BBB. b) Percentile transmigration of nanocarriers
at different time.
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In our study, TEER values of BBB remain closer to the standard 200
ohms/cm2 both at the beginning and end of experimental period, suggesting
unaffected integrity of BBB due to exposure of different nanoformulations (Table
3).

Table 3: Transendothelial electrical resistance (TEER) values of the in vitro BBB model
before and after treatment ML nanocarriers in the presence and absence of external
magnetic force

The transmigration pattern of nanocarriers was further verified by
measuring the iron concentration. Triton mediated liposomes breaking results in
release of encapsulated and/or uptaken Fe3O4 which is exposed to ammonium
thiocyanate following oxidation via ammonium persulfate. Quantification of
resulting iron-thiocyanate emits red color at 490 nm gives concentration of Fe3O4
uptaken by BBB cells. As evident from figure 35, consistent with the
transmigrability, higher iron concentration was found when external magnetic
force was used. This supports our observation that external magnetic force may
result in increased accumulation of ML nanocarriers at the BBB causing higher
transendothelial extravasation and/or receptor-mediated transmigration.
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Figure 35:

The Fe3O4 content in lower

chamber post-transmigration.

4.12.

Cytotoxicity of ML nanocarriers:

Percent viability of astrocytes and HBMVE cells remains unaffected due to
treatments of our nanocarriers (Figure 36). In the same line it has been
suggested that doses of MNPs within the permissible limit have non-significant
safety concerns and are biodegradable (Jain et al., 2008). This suggests that ML
nanoformulations possess required potential to be used as carrier for drug deliver
across BBB.

Figure 36:

Percent cell viability

of primary endothelial cells and
astrocyte cells 24 and 48 hrs
post-treatment

with

different

concentration of ML nanocarriers.
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4.13. BBB transmigration and efficiency of BDNF nanoformulations:
We evaluated the ability of MNPs-BDNF nanoformulations to cross the
BBB. As stated previously, free or MNPs bound BDNF were added to the apical
chamber of an established in vitro BBB model and transmigration was influenced
by applying external magnetic force beneath the lower chamber. The result
obtained by BDNF ELISA for the sample collected from the basal chamber show
that approximately 73% of the MNP bound BDNF was able to transmigrate
across BBB (Figure 37A). This corresponds to 3.5 folds higher transmigration
than free BDNF. Our results suggest that transmigration ability of BDNF across
BBB increased significantly when MNPs were used as carriers. Again, we
verified the integrity of BBB and as demonstrated previously, the BBB remained
undamaged. A TEER reading of 280.4 and 276.5 were obtained respectively for
pre- and post-transmigration (Figure 37B).

Figure 37:
transmigration

(A). Percentage
of

free

and

MNP-BDNF nanoformulations.
(B). TEER values of the in vitro
BBB model before and after
treatment of free and MNPBDNF nanoformulations.
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Furthermore, we studied whether transmigrated BDNF retains functional
efficiency or not? As such, CREB expression in the astrocytes on the basal side
of BBB was quantified. Consistent with the transmigration ability, we found that
treatment with BDNF alone did not induce any change in CREB expression in
astrocytes in the basal side. In contrast, treatment with MNP-BDNF showed an
upregulation of CREB (TAI=1.67±0.12; p=0.007, figure 38). This result confirmed
that unlike free BDNF, BDNF bound to MNP is able to cross BBB and is effective
in its function.

Since astrocytes of established in vitro BBB model remains in

direct contact of media from lower chamber, it is expected that transmigrated
BDNF in the lower chamber will exert its effect on these cell. In the same line,
magnetic drug targeting of anticancer drugs to treat brain carcinoma has already
been reported (Chertok et al., 2008). Thus, targeted delivery of BDNF in brain
through an effective carrier such as MNPs would provide significant therapeutic
benefits for treatment drug addiction and/or neuroAIDS.

Figure 38:

Trans-accumulation
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MNPs-BDNF

nanoformulations on CREB expression
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expression is significantly upregulated
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treatment

nanoformulation
effective

of

MNP-BDNF

which

transmigration

across BBB via nanocarrier.
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5. Summary:
As stated by President Nixon in 1971, drug abuse is America’s number one
enemy. In fact, drug abuse is a serious global problem which speeds up the
spread of many blood-borne diseases including HIV. Considering the highintensity of affected populations, lack of treatment, and unrepairable social costs
associated with the drug abuse and HIV infection, it is quintessential to develop
better strategies for their preventions. In this dissertation I investigated a novel
MNPs-based

drug

delivery

system

for

delivery

of

anti-addiction,

and

neuroprotective drugs across the BBB. It is anticipated that the active from of
these drugs could be delivered across BBB. Successful delivery of anti-addiction
agents e.g. CTOP (an opioid antagonist) may reduce the addictive effect of
abusive drugs and block the synergistic neurotoxicity during HIV infection.
Similarly, delivery of neuroprotective agent, brain derived neurotropic factor
(BDNF), could be of therapeutic benefit in the treatment of both, drug addiction
and HIV infection. Further, ultrasmall magnetic nanoparticles was synthesized
and loaded into PEGylated liposome which could provide nanoplatform for
enhanced BBB transmigration of drugs. Drugs bound to naked MNPs may either
be decomposed due to metabolic activity of peripheral circulation (blood) or be
cleared or entraped by reticuloendothelial systems (liver, stomach, gut, lymphoid,
etc.) before it reach to the brain. In this contrext, magnetized-liposome (liposomal
encapsulation of MNPs bound drugs) is advantageous in many ways: (a)
Liposomes coating protects drugs from metabolic insults of blood circulation and
reduces their uptake by liver, stomach, gut, lymphoid, etc. This remarkably
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improves the stability and bioavailability of drugs in body. (b) Magnetized
liposomes can be easily transported across BBB under influence of external
magnetic force. (c) While drugs attached with MNPs are encapsulated in the
liposomal core, additional free drugs can also be supplemented on the liposomes
wall (phospholipid bilayers). Thus, per unit drug-loading efficiency of magnetized
nanocarrier is enhanced.
Our developed nanocarriers seem to deliver improved level of
therapeutics in the brain which is the common target organ for both HIV and drug
abuse. It is expected that using our innovations, suppression of pathogenesis in
drug addicted and HIV patients could be significantly improved and, in turn, it
may add to achieve near-normal life expectancy for treated individuals. Thus,
transfer of this strategy in clinical settings may be beneficial for these major
social problems. A proposed model of drug delivery via magnetic nanocarriers
has been shown in figure 39. Importantly, this strategy could be applied to other
brain diseases leading to a healthier lifestyle.

Many brain diseases such as

Huntington’s, Epilepsy, Stroke, Parkinson’s, Alzheimer’s, Multiple Sclerosis,
Brain Tumors, etc. remain untreated, mainly due to impenetrability of drug or
existing drug-delivery techniques across BBB. Thus, our magnetic nanocarriers
could have universal applicability for drug-targeting in the brain in a non-invasive
manner for many brain diseases. Additionally, magnetic field generated by MNPs
under the influence of magnetic force could stimulate inactivated neurons in
Parkinson’s, Alzheimer’s Stroke, etc. MNPs could also be used for imaging via
MRI which can tell about pathological conditions and its progression.
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Thus,

MNPs could be developed as a polypharmacological technique where it could
simultaneously deliver drugs, diagnose pathological progression, and stimulate
degenerating neurons in various brain diseases.

Figure 39: Proposed shcematic of magnetic nanoparticles based drugs delivery across BBB.
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6. Future directions
Based on the in vitro observations we assume that, under the influence of
external magnetic force, drugs loaded magnetic nanocarriers in the form of
magnetized-liposomes can either directly transport across the BBB. As such,
magnetic hybrid nanoformulations (magnetized-liposomes) seem to be more
practical nanovehicles for drug delivery to the brain and its applicability in animal
model must take place. It will allow knowing the feasibility of our developed
nanocarrier to go across the BBB in the physiological relevance condition.
Following completion of work on mouse model, its applicability in monkey model
must be evaluated; success of which may lead to the clinical applications of our
developed nanocarriers (figure 40). It is expected that using our innovations,
suppression of pathogenesis in drug addicted and HIV patients could be
significantly improved and, in turn, it may add to achieve near-normal life
expectancy for treated individuals. Thus, transfer of this strategy in clinical
settings may be beneficial for these major social problems. Importantly, this
strategy could be applied to other brain diseases leading to a healthier lifestyle.

Figure 40. Schematic of future work with nanoformulations from in vitro study to the clinical trial
(Googleimages).
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